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ABSTRACT 
 
 
QUANTITATIVE MASS SPECTROMETRIC INVESTIGATIONS OF PROTEIN 
BIOMARKERS: SERUM THYMIDINE KINASE 1 AND HUMAN OSTEOPONTIN 
 
 
By Morse Faria 
A dissertation submitted in partial fulfillment of the requirement for Doctor of Philosophy degree 
at Virginia Commonwealth University 
 
Virginia Commonwealth University, 2014 
 
Major Director: H. Thomas Karnes, Ph.D. 
Professor, Department of Pharmaceutics 
 
 
Mass spectrometry is being increasingly used in biomarker research mainly due to its ability to 
achieve high selectivity coupled with high sensitivity. This dissertation focuses on quantitative 
mass spectrometric investigations of two protein biomarkers i.e. serum thymidine kinase 1 (TK1) 
and human osteopontin (hOPN). 
  
 
 
A liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) method for 
measuring the activity of TK1 in serum by monitoring the conversion of a TK1 specific 
exogenous substrate, 3’-deoxy-3’-fluorothymidine (FLT), to its mono-phosphorylated form 3’-
deoxy-3’-fluorothymidine monophosphate (FLT-MP). A method to quantify FLT-MP on LC-
MS/MS was developed and validated. The method was linear over the range of 2.5-2000 ng/mL 
with a mean correlation coefficient of 0.9935.  The applicability of the developed method was 
demonstrated by measuring TK1 activity in serum from hepatocellular carcinoma (HCC) patients 
and age-matched controls.  
Another method was developed and validated for quantifying hOPN from plasma using 
immunoaffinity isolations coupled with microflow LC-MS/MS. A biologically relevant tryptic 
peptide ‘GDSVVYGLR’ was used as a signature peptide. The method was validated over a 
range of 25-600 ng/mL. A stable isotope labeled (SIL) peptide GDSVVYGLR* and an extended 
SIL peptide TYDGRGDSVV*YGLRSKSKKF’ were evaluated as internal standards (IS) to 
account for digestion variability. In the digestion variability studies, the use of extended SIL 
peptide as internal standard limited the total variability within ±30% in comparison to ±70% 
when the SIL-peptide was used. The applicability of the validated method was demonstrated by 
analyzing plasma samples obtained from 10 healthy individuals and 10 breast cancer patients.  
In a proof of concept investigation, a SIL-peptide was evaluated as an internal standard to 
compensate for immunocapture variability during quantification of hOPN by immunoaffinity 
coupled LC-MS/MS. Immunocapture variability was induced by varying the antibody amount 
per well. The use of SIL-peptide reduced the immunocapture variability from ±81% to ±37%   
immunocapture variability. 
  
 
 
In addition, an attempt was made to develop a cell based system to evaluate tobacco products for 
cardiovascular risk based on the LC-MS/MS measurement of secreted osteopontin and MMP-3 
cleaved osteopontin fragments. However, in our preliminary investigations did not yield 
detectable levels of the secreted osteopontin concentrations in the cell culture studies and hence 
this study was terminated. 
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 CHAPTER 1 
 
 
1 MASS SPECTROMETRY BASED PROTEIN BIOMARKER QUANTIFICATION 
 
 
1.1 INTRODUCTION 
Biomarkers are used clinically for diagnosis, patient stratification, and therapy selection and for 
determination of a surrogate end point in clinical trials (Fleming, et al. 2012, Goodsaid, et al. 
2007, Pletcher, et al. 2011). The pharmaceutical industry is optimistic that increased biomarker 
applications will enable faster and more successful drug development (Kola, et al. 2004, Lee, et 
al. 2009). However, one of the limitations in the use of biomarkers in clinical settings and in 
drug development, has been the lack of good quantitative assays (Drucker, et al. 2013, 
Makawita, et al. 2010). Traditionally, immunoassays have been used for targeted quantification 
of large molecule biomarkers, but issues with selectivity, robustness and long development time 
associated with these assays have led to the search for alternative methods for measurement of 
biomarkers. (Hoofnagle, et al. 2009, Makawita, et al. 2010, Pan, et al. 2009, Rauh 2012, Wang, 
et al. 2009). Over the last decade, there has been a tremendous increase in the use of mass 
spectrometry for targeted quantification of biomarkers in clinical settings (Lee, et al. 2009, 
Makawita, et al. 2010, Pan, et al. 2009, Ramanathan, et al. 2011, Rauh 2012, Wang, et al. 2009). 
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In this chapter, we will review the current practices for development and validation of protein 
biomarkers from biological matrices using mass spectrometry based methods. 
1.1.1 Biomarkers – Definition and Classification 
Biomarker is a combination of the words ‘biological’ and ‘marker’. Over the last two decades, 
many definitions have been attributed to the word biomarker.  The official National Institute of 
Health (NIH) definition is: ‘a characteristic that is objectively measured and evaluated as an 
indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a 
therapeutic intervention” (Atkinsons, et al. 2001).  Biomarkers have further been classified into 
three types: prognostic, predictive and surrogate end biomarkers (Strimbu, et al. 2010, Weigel, et 
al. 2010). Prognostic biomarkers are used to forecast the natural history of a disease irrespective 
of treatment. They are used for diagnosis and patient stratification. Predictive biomarkers are 
used to suggest the population which is likely to benefit from a particular treatment. For 
example, expression of the estrogen receptor (ER), progesterone receptor (PR), and human 
epidermal growth factor receptor 2 (Her2/neu) are the three most commonly used prognostic and 
predictive biomarkers in breast cancer patients (Strimbu, et al. 2010, Weigel, et al. 2010).  Over 
expression of ER and/or PR in breast cancer patients is used as a predictive biomarker in therapy 
selection since these patients would have a higher likelihood of benefit from endocrine based 
therapy such as tamoxifen (Strimbu, et al. 2010, Weigel, et al. 2010). Some biomarkers like 
Her2/neu can have both prognostic and predictive value (Strimbu, et al. 2010, Weigel, et al. 
2010). Her2/neu overexpression is associated with poor prognosis and is indicative of tumor 
relapse and shorter overall survival in breast cancer patients. Her2/neu is the target of the anti-
cancer therapeutic monoclonal antibody trastuzumab (Herceptin), and thus, Her2/neu status can 
be used to predict the effectiveness of trastuzumab. Thus, Her2/neu status can also be used for 
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selection of therapy.  In conclusion, prognostic and predictive biomarkers are used for diagnosis, 
patient stratification and therapy selection (Buyse, et al. 2010, Strimbu, et al. 2010, Weigel, et al. 
2010) 
Surrogate endpoint biomarkers provide early prediction of a clinical endpoint and/or the effect of 
treatment on the endpoint. Surrogate endpoint markers are useful when the primary end point is 
undesirable (death) or when the number of events is so small that one cannot obtain statistically 
significant numbers in a clinical trial. A classic example of a surrogate end point marker is blood 
cholesterol concentration (Psaty, et al. 1999). Drugs such as simvastatin can use ‘reduction in 
blood cholesterol’ as a surrogate endpoint to approve a clinical trial as the primary endpoint (i.e. 
stroke, heart attack or death) is undesirable. 
1.1.2 Quantification of Protein Biomarkers 
Biological or pathological status of a system can be evaluated by measuring the concentrations of 
biomolecules such as lipids, proteins and nucleic acids. These biomolecules are involved in 
signaling pathways and thus altered expression or activity of these biomolecules can have an  
impact on biological status. Hence, these molecules are extensively used as biomarkers. Proteins 
are ultimate functional units for various signaling pathways in cells. Protein levels can be 
predicted by quantifying mRNA levels but it has a number of limitations (Dhingra, et al. 2005, 
Rogers, et al. 2008). The mRNA levels may not correlate with the protein level due to inefficient 
translation or to the degradation of mRNA. Additionally, the proteins may not be functionally 
active, because its activity may be regulated by post-translational modifications. Proteins may 
also be susceptible to degradation or complexation. Hence, measuring protein concentration or 
its activity is preferred (Dhingra, et al. 2005, Rogers, et al. 2008). 
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Protein biomarkers can be measured from tissue or blood (plasma/serum). Protein biomarkers 
found in plasma/serum are preferred over tissue biomarkers as it is comparatively less invasive to 
obtain a blood sample than a biopsy sample of a solid tissue. As a result of ease of availability, 
plasma/serum biomarkers can be effectively used for screening the general population for early 
disease detection, patient stratification and therapy monitoring.   
Quantification of protein biomarkers is traditionally carried out using immunoassays. In 
particular, Enzyme Linked Immuno Sorbent Assay (ELISA), has been the standard for protein 
quantification from biological fluids (Makawita, et al. 2010). Due to high sensitivity, high 
throughput and cost effectiveness, sandwich ELISAs have been the primary choice for protein 
quantification. ELISA requires a pair of well characterized antibodies having high specificity for 
the protein biomarker. One of the major drawbacks of ELISA has been its long development 
time (1-2 years) and the huge development cost (100,000’s-1,000,000’s) (Wang, et al. 2009).  
This has resulted in restricting the number of biomarker candidates that can advance from the 
biomarker discovery phase to the biomarker validation phase. Immunoassays have additional 
intrinsic  challenges arising from antibody cross-reactivity, the presence of post-translational 
modifications on the analyte protein, interferences from autoantibodies and anti-reagent 
antibodies, and the high-dose hook effect (Hoofnagle, et al. 2009). This can lead to variable and 
inaccurate measurements, which may result in misleading clinical interpretations and decisions 
(Hoofnagle, et al. 2009). 
Mass spectrometry, as a quantitative tool, was largely restricted to the evaluation of small 
molecules untill the 1990’s. "This was due to the lack of good soft ionization techniques that are 
required for large molecule quantification. The development of soft ionization techniques such as 
electrospray ionization (ESI) and matrix assisted laser desorption ionization (MALDI) facilitated 
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the use of mass spectrometry for analysis of peptides and proteins (Makawita, et al. 2010, 
Ramanathan, et al. 2011, Rauh 2012).  In the last decade, mass spectrometry based bioanalysis 
has played a major role in biomarker discovery and validation. Advancements in mass 
spectrometric instrumentation and the better quantification strategies has resulted in a shift of 
biomarker analysis from immunoassays to mass spectrometry (Makawita, et al. 2010, 
Ramanathan, et al. 2011, Rauh 2012).   
Tandem mass spectrometry using the selected reaction monitoring (SRM) mode, has been well 
established for quantification of small molecules, primarily, due to its high specificity and 
sensitivity (Rauh 2012). In the SRM mode, analyte precursor ions and product ions, obtained 
after fragmentation of the precursor ion, are selected based on their mass to charge ratio in the 
mass analyzer. The SRM mode’s high specificity is due to the low probability of two molecules 
having the same mass to charge ratio and fragmenting under standardized conditions to form 
fragments of the same mass to charge ratio. Thus, mass spectrometry based quantification using 
the SRM mode provides high selectivity and specificity. In addition, it has the ability to measure 
absolute levels of post-translational modifications or protein isoforms. These assays involve 
lower costs and development time in comparison to ELISA (Makawita, et al. 2010).  In addition, 
these assays allow easy multiplexing to measure multiple analytes in a single measurement. The 
multiplexing ability provides the possibility of evaluating multiple biomarker lead molecules 
during the validation phase, allowing a relief in the bottleneck in biomarker discovery. Another 
advantage that mass spectrometry provides is the ease of transferability of methods between 
matrices and species in comparison to immunoassays. A comparison of immunoassay and LC-
MS/MS for peptide and protein quantification is given Table 1-1. 
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Table 1-1: Comparison of immunoassay and LC-MS/MS for peptide and protein 
quantification 
 LC-MS/MS Immunoassay 
Antibody Requirement Not Required unless method involves 
immunoaffinity enrichment 
A well characterized pair of 
antibodies required for ELISA 
Development Time 2 Weeks – 2 Months Months -2 years 
Development Cost Moderate High 
Specificity High Moderate 
Dynamic Range 10
3
-10
5
 10
2
 
Variability Low High 
Multiplex Capability High Low 
Ability to measure PTMs High Low 
Sensitivity ng/ml pg/ml 
Throughput Capability Moderate High 
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1.2 MASS SPECTROMETRIC BASED PROTEIN QUANTIFICATION 
Mass spectrometry based protein quantification is normally carried out using a stable isotope 
dilution approach (Barr, et al. 1996). Most of the current targeted mass spectrometry based 
quantification involves digestion of the analyte protein to yield one or more unique tryptic 
peptides commonly referred to as signature peptides. The signature peptide is then used as a 
surrogate analyte and quantified using the mass spectrometry platform. This approach of 
digesting the protein into peptides prior to its instrumental analysis is referred to as bottom-up 
quantification. A stable isotope labeled (SIL) form of the signature peptide/protein may be added 
during sample processing for internal standardization. These peptides are commonly referred to 
as SIL internal standards (SIL-IS) (Li, et al. 2012, Makawita, et al. 2010, Rauh 2012). SIL-IS  
peptides are synthetically obtained by incorporating a stable isotope of 
13
C and 
15
N on one 
selected amino acid of the chosen signature peptide sequence (Li, et al. 2012, Makawita, et al. 
2010, Rauh 2012). The resulting SIL-IS will have physicochemical properties similar to the 
analyte molecule, thus resulting in similar chromatographic separation, ionization efficiency and 
fragmentation pattern. As the isotope label on the SIL-IS peptide results in a difference in its 
mass with respect to the signature peptide, these peptides can be differentially detected using 
mass spectrometry. The ratio of analyte intensity and internal standard intensity is considered as 
the final response. Any variation, due to sample complexity or analytical conditions, affecting 
the intensity of the analyte will have a proportional effect on the internal standard, thus ensuring 
that the final response ratio remains constant. This response ratio evaluation is the fundamental 
principle of isotope dilution quantifications (Zhang, et al. 2014). This protein quantification 
strategy that relies on the use of a synthetic stable isotope labeled internal standard peptide that 
can mimic the signature peptide produced during proteolysis wherein the  final response is 
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measured as the response ratio between the signature peptide and SIL-IS peptide, is referred to as 
the Absolute Quantification (AQUA) strategy. An AQUA strategy was first illustrated by Gerber 
et al. in 2003 wherein the absolute levels of low abundance protein and a phosphorylated protein 
were quantified from whole cell lysates after an initial separation using SDS/PAGE (Gerber, et 
al. 2003). Since then there have been a number of alternate strategies for absolute quantifications 
which are discussed in detailed further in the text under internal standardization. 
1.2.1 Selection of Signature Peptides 
In bottom-up protein quantification, selection of a signature peptide (s) is a critical part of 
method development. Some important characteristics of a signature peptide, as summarized by 
van den Broek et al (2013), are as follows: (1) It should be unique and specific to the target 
protein (2) It should be formed reproducibility during enzymatic digestion (3) It should be stable 
throughout the entire analytical procedure (4) It should be sufficiently resolved from background 
interferences during chromatographic separations (5) It should be easily ionized and dissociated 
and have sufficient sensitivity during MS/MS analysis. Trypsin is the most commonly used 
enzyme to carry out proteolytic digestion due to its selective cleavage on the c-terminus of the 
positively charged amino acid residues lysine or arginine (Evnin, et al. 1990, Olsen, et al. 2004). 
A number of criteria are used during selection of the signature peptides. Tryptic peptides having 
a chain length between 5-25 amino acids are preferred to reduce charge state distribution and 
provide adequate retention and MS/MS fragmentation. Tryptic peptides containing amino acid 
residues with potential post-translational modification (PTM) sites are usually avoided due to a 
potential change in peptide mass that would affect reproducible quantification. However, if the 
intended purpose is to quantify a post-translational modification, a tryptic peptide containing the 
specific PTM is selected (Gerber, et al. 2003, Kirkpatrick, et al. 2005, Liu, et al. 2013). Tryptic 
  
9 
 
peptides containing amino acids susceptible to oxidation such as methionine and tryptophan are 
avoided as chemical modifications of these molecules can result in a change in its mass and thus 
can affect method reproducibility. Usually tryptic peptides containing cysteine residues are 
avoided as they undergo iodoacetamidation (Switzar, et al. 2013). However, methods using 
signature peptide containing a cysteine residue have been reported after accounting for any mass 
change occurring prior to mass spectrometric detection. (Enjalbert, et al. 2013, Palandra, et al. 
2013, Zhang, et al. 2011).  Additionally, peptides containing ragged ends or dibasic ends next to 
each other (such as in Arg-Arg, Lys-Lys or Arg-Lys) should be avoided as they are known to 
result in missed cleavages (Brownridge, et al. 2011a, Lawless, et al. 2012, Switzar, et al. 2013, 
Wu, et al. 2011) . This could be due to the inability of trypsin to act as a dipeptidyl peptidase 
(Brownridge, et al. 2011a, Lawless, et al. 2012). Various commercially available software and 
databases that can perform in-silico digestion, verify uniqueness of the tryptic peptides and 
determine mass spectrometric parameters are well summarized by Colangelo et al. and are listed 
in Table 1-2 (Colangelo, et al. 2013). After in-silico digestion studies, multiple tryptic peptides 
are selected as potential signature peptides and evaluated for digestion reproducibility, ionization 
intensity and process stability. Digestion optimizations are carried out with recombinant protein. 
Chromatographic and mass spectrometric optimization are done using synthetically obtained 
peptides. Chromatographic optimization during signature peptide selection ensure adequate 
retention and resolution from matrix components. Mass spectrometric optimizations will involve 
selection of the mass transitions that are specific to the analyte along with sufficient signal 
response. In the case of the unavailability of a recombinant protein, digestion optimization may 
be carried out with biologic samples containing the analyte protein. It is advisable to establish the 
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selectivity of the signature peptide in the desired matrix using the optimized LC and mass 
spectrometric conditions during method development. 
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Table 1-2: List of software used for signature peptide selection 
Software Use Name Vendor 
Database 
search 
Basic Local Alignment 
Search Tool (BLAST) 
National Center for Biotechnology Information 
PeptideAtlas Institute for Systems biology (IBS) 
Protein Prospector University of California, San Francisco 
SRMAtlas IBS 
PRIDE 
Martens,  European Molecular Biology 
Laboratory 
GPMdb Global Proteome Machine Database 
NIST peptide mass Spectral 
libraries 
National Institute of Standards and 
Technology (NIST) 
PABST Seattle Proteome Center 
In-Silico 
Digestion and 
Signature 
Peptide 
Transition 
Selection 
Skyline MacCoss Lab, University of Washington 
MRMPilot ABSciex 
Pinpoint Thermo Scientific 
MRMaid Bessant, Cranfield University 
Enhanced Signature Peptide 
Predictor (ESP) 
Broad Institue 
MaRiMba Seattle Proteome Center 
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1.2.2 Internal Standardization 
The selection of an internal standard is an important aspect of the method development process 
for LC-MS/MS quantification of proteins. Internal standards compensate for variation during 
sample processing and instrumental response fluctuations. A number of IS strategies for mass 
spectrometry based protein quantification have been proposed, previously and reported in several 
review articles (Bronsema, et al. 2012, Brun, et al. 2009, Pailleux, et al. 2012, van den Broek, et 
al. 2013a).  
1.2.3 SIL-Protein IS 
 A stable isotope labeled (SIL) form of the analyte protein is the most ideal IS for absolute 
quantification of proteins since it will have the same physicohemical behavior throughout the 
analytical procedure. SIL-proteins can be obtained by incorporating stable isotope labeled amino 
acids into the target protein, or PSAQ (Protein Standard Absolute Quantification) standard (Ong 
2002, Picard, et al. 2012). This can be achieved using metabolic labeling by incubating cells in a 
medium containing stable isotope labeled amino acids popularly known as Stable isotope 
labeling by amino acids in cell culture (SILAC) (Ong 2002). Alternatively, SIL-proteins can also 
be made by in vitro protein synthesis in a cell free system (Brun, et al. 2007). If the analyte 
protein is small it can be chemically synthesized (Jian, et al. 2013).  SIL-protein standards can 
compensate for immunoaffinity isolation, enzymatic digestions, pre-analytical treatments and 
final LC-MS/MS analysis. Hence, analysis carried out with SIL-proteins will be reproducible and 
robust.  A major restriction in the use of SIL-proteins as ISs for biomarker quantification is their 
commercial unavailability or the high cost of production. 
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Alternatively, a structural protein analogue can also be used as an internal standard (Halquist, et 
al. 2011a, Li, et al. 2011a). It would compensate partially for any digestion variability, however 
its major drawback would be its limited ability to compensate for LC-MS/MS variability.  
1.2.4 SIL-peptide IS 
A SIL form of the signature peptide (SIL-peptide) is the most commonly used internal standard 
during protein quantification.  A SIL-peptide IS contains amino acids labeled with the stable 
isotopes of 
13
C or 
15
N thus resulting in peptide analogues which are physiochemically identical to 
the signature peptide but can be easily distinguished due to the mass difference. SIL-peptide ISs 
can efficiently compensate for extraction recovery, peptide instability and LC-MS/MS 
variability. However, unlike a SIL-protein it does not account for proteolytic digestion variability 
or any immunoaffinity based purification processes (Brun, et al. 2009, Li, et al. 2012). The 
major advantage of using a SIL-peptide is that these can be synthetized at relatively low cost. In 
fact, custom synthesized SIL-peptides can be easily obtained from various commercial sources.  
A SIL-peptide IS is usually added before enzymatic digestion as it can account for peptide 
stability and extraction recovery. However, if a recombinant form of the biomarker is not 
available, protein concentrations are calculated  stiochometrically, solely based on the known 
molar concentration of the SIL-peptide used, in such instances, the IS is added post digestion to 
obtain reproducible peptide quantification (Domanski, et al. 2012, Keshishian, et al. 2007). 
1.2.5 Extended SIL-peptide 
Variation in digestion efficiency can be accounted for with the use of an extended SIL-peptide 
which have cleavable groups flanking either side of side of a SIL-peptide (Barnidge, et al. 2004, 
Neubert, et al. 2013, Ocana, et al. 2010). Generally, the cleavable groups consist of three to six 
amino acids residues from the original protein sequence at both the N- and C- terminus (Kushnir, 
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et al. 2013, Neubert, et al. 2013, Ocana, et al. 2010). The addition of an extended SIL-peptide IS 
prior to digestion provides a more cost effective alternative to compensate for variability in 
digestion efficiency, extraction recovery, LC-MS/MS analysis and peptide stability. 
Beynon et al. developed the QonCAT (Quantification concatemer) approach to produce 
recombinant proteins that have multiple SIL signature peptides linked together by using an 
synthetically obtained artificial gene (Beynon, et al. 2005). This allows application to a large 
group of proteins and is useful for multiplexed methods. However, its ability to compensate for 
digestion efficiency may be limited as differences may exist between the QconCAT polypeptide 
and the analyte proteins with respect to the accessibility of the proteolytic site and digestion rates 
(Brownridge, et al. 2011b). 
1.2.6 Sample Preparation  
Plasma and serum are highly complex biological fluids. In fact, in serum, 20 of proteins 
comprise 99% of total protein content and the concentrations of all proteins demonstrate  more 
than 12 orders of magnitude (Makawita, et al. 2010). Analysis of direct digests of serum or 
plasma would be ideal as it would involve minimal sample preparation. However, matrix effects 
and interferences from other highly abundant proteins would adversely affect the limit of 
quantification and specificity of these mass spectrometric methods. Thus, sample clean-up prior 
to enzymatic digestion is an essential part of protein quantification. 
1.2.6.1 Protein Purification 
1.2.6.1.1 Non-antibody-based protein purification 
For proteins smaller than 15 kDa, various strategies which are not specific for protein 
purification can employed. Partial protein precipitation using organic solvents along with 
surfactants is used as a simple sample purification technique used for smaller proteins or peptides 
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(Halquist, et al. 2011a, Murao, et al. 2007, Sleczka, et al. 2012, Wu, et al. 2011). Protein 
precipitation could have low recovery due to losses as a result co-precipitation, which would be a 
drawback. Solid phase extraction (SPE) is another purification technique that is employed solely 
or along with other purification techniques for sample clean up wherein the analyte is a smaller 
protein or peptide (Barton, et al. 2010, Halquist, et al. 2012, Jian, et al. 2013, Sleczka, et al. 
2012, Yang, et al. 2009).    
1.2.6.1.2 Abundant Protein Depletion 
The plasma proteome is comprised of a number of proteins having a concentration range with 
more than 10 orders of magnitude (Anderson, et al. 2002). Albumin is a protein that covers 
approximately 50% of the total protein content (Anderson, et al. 2002). In fact, it is estimated 
that 99% of the serum’s total protein mass is due to the top 20 most abundant proteins. Several 
commercial kits are available which use immunoaffinity depletion to selectively remove serum 
albumin, immunoglobulins and other high abundant proteins (Anderson, et al. 2006, Echan, et al. 
2005, Keshishian, et al. 2009, Polaskova, et al. 2010). These kits have shown to reduce protein 
content by up to 85% (Echan, et al. 2005). The high costs of these kits and recovery issues have 
been the major drawback of this approach (Fortin, et al. 2009, Keshishian, et al. 2007). 
Abundant protein depletion has been used in a number of biomarker quantification methods 
(Fortin, et al. 2009, Kuhn, et al. 2004, Yu, et al. 2012). Recently, Lui et al. showed that 
isopropanol with 1.0% trichloroacetic acid was effective in removing 95% of the total albumin 
in human plasma samples while retaining 60-100% of the three analyte proteins that were 
evaluated.  The recovery using this approach was found to be better than commercially available 
albumin depletion kits (Liu, et al. 2014). 
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1.2.6.1.3 Immuno-capture enrichment 
Use of specific antibodies directed toward the analyte protein can be used for isolating the 
analyte molecule from a complex biological matrix. These enrichments may be carried out with 
single or multiple antibodies depending on the availability of analyte specific antibodies and the 
amount of selectivity required. Although this technique requires resources and development time 
to produce the necessary antibodies, it provides sufficient purification to achieve quantification 
of low abundance proteins from plasma (Berna, et al. 2007, Callipo, et al. 2010, Keshishian, et 
al. 2007, Ocana, et al. 2010, Winther, et al. 2009). Low recoveries and a lack of specificity are 
some of the issues seen during immune-capture enrichment (Adrait, et al. 2012, Dubois, et al. 
2007). Another drawback is that the internal standardization of the immuno-capture step requires 
the use of a SIL-protein (Bronsema, et al. 2012, Pailleux, et al. 2012) . 
Anderson et al. introduced a Stable Isotope Standards with Capture by Anti-Peptide Antibodies 
(SISCAPA) strategy wherein immuno-capture enrichment is directed towards a signature peptide 
after digestion using anti-peptide antibodies (Anderson, et al. 2004). This technique allowed 
quantification of low abundance proteins from plasma, however required the production of 
antibodies specific to the signature peptide. Some methods have employed this type of immuno-
capture online using specialized columns containing analyte specific antibodies (Berna, et al. 
2006, Dufield, et al. 2012, Neubert, et al. 2010). 
1.2.6.2 Enzymatic Digestion 
Most protein quantitative LC-MS/MS methods involve enzymatic digestion of the proteins to 
yield smaller peptides which can be easily quantified by commercially available quantitative 
mass spectrometers. Some smaller proteins or polypetides may be analyzed without enzymatic 
digestions (Becher, et al. 2006, Chambers, et al. 2013, Dubois, et al. 2007, Wang, et al. 2012a). 
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A typical protein digestion procedure involves denaturation, reduction and alkylation followed 
by proteolysis. Denaturation is carried out to unfold the protein so that it can be easily accessible 
to the proteolytic enzyme. Urea is the most commonly used for denaturation during protein 
quantification. Alternatively, denaturation has been achieved using other chaotropic agents such 
as guanidine HCl, surfactants such as sodium deoxycholate, organic solvents such as methanol 
and heat (95ºC) (Hoofnagle, et al. 2008, Switzar, et al. 2013, Wu, et al. 2011, Yang, et al. 2009, 
Yu, et al. 2012). Reduction of the protein is carried out using dithiothreitol to break the disulfide 
linkages between cysteine residues. The resulting free thiol groups are then derivatized using an 
alkylating agent such as iodoacetamide in order prevent formation of disulfide linkages. 
Trypsin is the most commonly used enzyme for protein digestions primarily as tryptic peptides a 
c-terminal basic residue that favors ionization. In addition, average tryptic peptides have lengths 
suitable for detection on commonly used quantitative mass spectrometers (Zhang, et al. 2014). 
However, other enzymes such Lys-C, Arg-C, pepsin, chymotrypsin can be used when a specific 
cleavage is required (Cingoz, et al. 2010, Liu, et al. 2011, Lu, et al. 2009, van den Broek, et al. 
2007). Sequencing or proteomics grade trypsin is normally used as it has higher digestion 
efficiency. Additionally, it is treated to prevent autolysis that can result in unwanted cleavage. To 
improve digestion efficiency, different approaches have been illustrated including high 
temperature, microwave assisted digestion and use of organic solvents (Berna, et al. 2009, Li, et 
al. 2009). The  ‘pellet digestion’ method is a simplified method in which the proteins are 
precipitated using an organic solevent like acetonitrile to form a pellet and the supernatant 
containing interfering molecules such as phospholipids are discarded. This method provides an 
easy, efficient way of performing a fast clean-up and has resulted in improved digestion 
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efficiency in comparison to direct digestion (Duan, et al. 2009, Ouyang, et al. 2012, Yuan, et al. 
2012, Yuan, et al. 2013).   
 
1.2.6.3 Strategies for LC-MS/MS Sample Preparation 
A number of reviews have compiled various strategies used for protein quantification using LC-
MS/MS (Ackermann, et al. 2007, Anderson, et al. 2006, Brun, et al. 2009, Gucinski, et al. , 
Kirkpatrick, et al. 2005, Li, et al. 2012, Makawita, et al. 2010, Rauh 2012, Ruan, et al. 2011, van 
den Broek, et al. 2013a, Wang, et al. 2009, Zhang, et al. 2014). Figure 1-1 illustrates a decision 
tree to choose an appropriate sample preparation strategy. For smaller proteins simple techniques 
such as protein precipitation and solid phase extraction would be the method of choice.  Protein 
purification methods are chosen depending on the analyte concentration, availability of 
purification tools (such as analyte specific antibodies) and the matrix. Depending on the analyte 
concentration, protein purification methods are selected. Many methods use a ‘double clean-up’ 
procedure wherein protein purification method is employed prior to digestion combined with a 
peptide purification step after digestion (Ahn, et al. 2009, Kushnir, et al. 2013, Neubert, et al. 
2013). 
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Figure 1-1: Decision tree for sample preparation for protein quantification using LC-MS/MS 
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1.2.7 Mass Spectrometric Instrumentation 
1.2.7.1 LC-MS/MS 
Mass spectrometry based protein quantification is primarily carried out on a high pressure liquid 
chromatography coupled with tandem mass spectrometry (LC-MS/MS) system. A list of recently 
published methods is summarized in various reviews (Ackermann, et al. 2007, van den Broek, et 
al. 2013a, Whiteaker, et al. 2010, Zhang, et al. 2014). The most widely used mass analyzers for 
quantification are triple quadropole (QqQ) and Quadrapole Ion Trap (QTrap using the multiple 
reaction monitoring (MRM) mode. In the MRM mode, analyte precursor ions and product ions, 
obtained after fragmentation of the precursor ion, are selected based on their mass to charge ratio 
in the mass analyzer. The MRM mode’s high specificity is due to the low probability of two 
molecules having the same mass to charge ratio and fragmenting under standardized conditions 
to form fragments of same mass to charge ratio. The non-scanning nature of the MRM mode 
allows increased sensitivity up to two orders of magnitude in comparison to the ‘full scan’ 
modes. MRM mode analysis can be used for polypetides and smaller proteins which have a mass 
less than 15 kda without digesting the protein.  Some low molecular weight proteins which have 
difficulty fragmenting have been analyzed using Pseudo-MRM i.e. monitoring the parent ion to 
parent ion transition using very low collision energy (Ji, et al. 2003, Zhu, et al. 2014). Unlike the 
MRM mode that relies on isolations based on parent ion and fragment ion mass to charge ratio, 
the pseudo-MRM approach relies on a single isolation, which can result in loss of specificity. 
Advances in mass spectroscopic sensitivity have been achieved mainly by increasing ionization 
efficiency and reducing losses during transmission from the ion source to the MS detector (Shi, 
et al. 2012, van den Broek, et al. 2013a).  Enhanced ionization efficiency has been achieved by 
using nano and micro flow rates and by using higher ion source temperatures. Ion transmission 
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efficiency has been improved by using guides or ion funnels (Shi, et al. 2012, van den Broek, et 
al. 2013a).  
Improved selectivity has been achieved using orthogonal separation modes such as Field 
asymmetric waveform ion mobility spectrometry (FAIMS) and differential mobility 
spectrometry (Arnold, et al. 2013, Shi, et al. 2012).  These ion mobility differentiation systems 
separate gas-phase ions based on their mobility differences in high and low electric fields 
primarily occurring due to the differences in size and shape of the ions. This orthogonal 
separation allows lowering matrix noise and in turn provides higher selectivity and sensitivity. 
Additional fragmentation modes measuring MS
3
 instead of MS
2
 fragment ions have been used in 
some methods to improve MS selectivity. A three to five fold lower LOQ has been achieved 
using the MS
3
 mode in comparison to the MS
2
 mode, especially, in cases where the limitation 
was due to matrix interference (Jeudy, et al. 2014, Lemoine, et al. 2012, Shi, et al. 2012). 
1.2.7.2  Full Scan Liquid Chromatography- High Resolution Mass Spectrometry (LC-
HRMS) 
Time of flight (TOF) and orbitrap mass analyzers are currently used to carry out HRMS 
quantification. (Gordon, et al. 1999, Gucinski, et al. , Liu, et al. 2011, Rochat, et al. 2013, Ruan, 
et al. 2011).  These mass analyzers have high resolving power (greater than 30K Full width at 
half maximum (FWHM)) and better than 3 parts per million mass accuracy. The high resolving 
power and mass accuracy allows resolution between analyte and background signals and thus 
can be used for analysis of intact protein molecules. Quantification is done based on peak areas 
using narrow mass windows (less than ± 0.05 Da) for the extracted ion chromatogram. Full scan 
LC-HRMS quantification is carried out usually for smaller proteins with molecular weights less 
than 15 kda (Zhang, et al. 2014). A typical protein spectrum containing multiple charge states 
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each having a distribution of its multiple isotopic peaks is seen in a full HRMS scan. High mass 
spectrometric resolution allows reproducible detection of individual peaks. The charge state and 
isotopic peak with the highest intensity and least background interference is chosen. 
Occasionally multiple peaks may be used to improve reproducibility and signal intensity. 
(Zhang, et al. 2014). LC-HRMS simplifies sample processing as one can avoid enzymatic 
digestions. A comparison of LC-MS/MS and LC-HRMS platforms for protein quantification was 
carried out by Dillen et al. (Dillen, et al. 2012). The study indicated that LC-HRMS had a lower 
sensitivity than an LC-MS/MS system but provided higher specificity.  LC-HRMS platforms can 
also be used to carryout quantitative and qualitative measurement simultaneously, thus providing 
the possibility of concurrent identification and quantification (L, et al. 2013, Ramanathan, et al. 
2011).  
1.2.7.3 Chromatographic System 
Liquid chromatography is used for separation of the protein or peptide mixture prior to mass 
spectrometric detection. Usually, reversed phase liquid chromatography (RPLC) is used to 
achieve separation of the peptide mixture (Ahn, et al. 2009, Barton, et al. 2010, Berna, et al. 
2009, Callipo, et al. 2010, Fortin, et al. 2009, Kuhn, et al. 2004, Neubert, et al. 2013, Ocana, et 
al. 2010, Whiteaker, et al. 2010, Winther, et al. 2009, Yu, et al. 2012), however, hydrophilic 
interaction liquid chromatography (HILIC) has been used to separate hydrophilic peptides. 
Columns used for peptide separation have particle size and dimensions similar to those used for 
small molecule quantification (Arsene, et al. 2010, Barnidge, et al. 2004, Barton, et al. 2010, 
Kirsch, et al. 2007, Kumar, et al. 2010, Yu, et al. 2012). However, specialized columns having 
pore size around 300 Å have been used especially wherein low molecular weight proteins need 
to be separated. In addition, a number of quantification approaches involving nano and micro 
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flow LC systems have been carried out using capillary columns having small inner diameters 
(I.D.) such as 75 and 150 µm (Ahn, et al. 2009, Keshishian, et al. 2007, Kuhn, et al. 2004, 
Neubert, et al. 2013, Whiteaker, et al. 2010). Recent developments in chromatographic 
hardware, mainly precise delivery pumps for micro and nano volumes, tighter system integration 
to reduce dead volumes, smaller diameter columns and newer LC-MS interfaces such as the 
Waters ionkey/MS separation device cartridge that holds a capillary column and a nanospray 
needle, have enabled use of nano and micro LC-MS/MS systems (Arnold, et al. 2013). The nano 
and micro-LC systems have better sensitivity due to higher electrospray efficiency obtained by 
the use of low flow rates, In addition, these systems utilize less solvent and thus help in cost 
reduction (Ahn, et al. 2009, Keshishian, et al. 2007, Kuhn, et al. 2004, Neubert, et al. 2013, 
Whiteaker, et al. 2010). 
Two-dimensional chromatographic separations, such as ion-exchange chromatography (IEC)-
RPLC or RPLC-HILIC, has been utilized to fractionate and clean up samples, thus improving 
sensitivity of detection (Gilar, et al. 2005, Keshishian, et al. 2007, Liu, et al. 2009, van den 
Broek, et al. 2013a, Zhang, et al. 2014). Additionally, most of the currently published methods 
have used column trapping prior to analytical separation to remove salts and highly hydrophilic 
peptides (Ahn, et al. 2009, Berna, et al. 2009, Callipo, et al. 2010, Kuhn, et al. 2004, Ocana, et 
al. 2010, Whiteaker, et al. 2010, Winther, et al. 2009). 
Most peptide LC-MS/MS quantifications are carried out using gradient mobile phase systems 
containing additives such as formic acid and trifluroacetic acid (TFA). Though TFA improves 
peak shape by reducing the interaction between peptides and the stationary phase, it is known to 
suppress electrospray ionization intensity (Apffel, et al. 1995). Ionization suppression by TFA 
can be circumvented by addition of acetic acid (0.5%) or propionic acid (1%), or by post-column 
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infusion of propionic acid and isopropanol. The large excess of weak acid protonates TFA anions 
back to neutral TFA molecules, thus freeing up the analyte ions from being paired with TFA 
anions (Apffel, et al. 1995, Shou, et al. 2005). Studies have shown that addition of 5% DMSO as 
a cosolvent can enhance ionization intensity through charge state coalescence (Meyer, et al. 
2012).  
1.3 ANALYTICAL VALIDATION OF BIOMARKER ASSAYS 
With the increasing use of biomarkers for diagnosis, patient stratification in clinical settings and 
higher acceptance of surrogate markers in clinical trials by regulatory bodies, there is a need for 
a greater focus on validation of quantitative biomarker assays (Buyse, et al. 2010, Lee 2009, Lee, 
et al. 2006). The objective of validating a method is to demonstrate that a particular method is 
reliable for the intended purpose. The intended use of biomarker data is an important 
consideration to determine the rigor of method validation. Thus, a ‘fit-for-purpose’ approach is 
most suitable for biomarker validation (Lee 2009, Lee, et al. 2006). In the last few years, there 
has been some consensus regarding LC-MS/MS method validation for biomarkers. Currently, 
biomarker assay validations using LC-MS/MS are being carried out using USFDA bioanalytical 
guidelines with intermediate acceptance criteria i.e. criteria ranging between those used for 
ligand binding assays (LBA) and small molecule bioanalytical assays (Bower, et al. 2014, Lee 
2009, Lee, et al. 2006, Stevenson, et al. 2013).  Some aspects that need to be considered prior to 
undertaking a ‘biomarker analytical validation’ are discussed below. 
1.3.1 Reference Standards 
 A reference should have high purity and should be well characterized and should represent the 
biologically relevant form of the analyte protein. Reference standards of smaller proteins like 
insulin and steroid hormones are commercially available in highly purified and well 
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characterized form (Lee, et al. 2006). However, most biomarkers are large proteins and their 
commercially available standards are often impure, poorly characterized and may not fully 
representative of the biologically relevant form. Additionally, there may be inconsistency in the 
purity and form between lots and manufacturers (Lee, et al. 2009). If the reference standards are 
obtained as recombinant proteins from non-eukaryotic cells, they may differ from the 
endogenous form as it will not have the necessary PTMs. If there exists no reference standard or 
if the reference standard is not a complete representative of the endogenous form, the method is 
referred to as quasi-quantitative (Lee, et al. 2006). 
1.3.2 Standard Calibrator matrix 
Biomarkers are endogenous molecules and selection of a blank matrix for preparation of 
calibrators and quality control samples is an important step in biomarker method validation (Lee, 
et al. 2006, Lee, et al. 2007, Lee, et al. 2009).  A simplified way is to pool together lots 
containing low endogenous concentrations. However, this would result in measureable 
concentrations of biomarker in the background and limit the evaluation of lower limits (van de 
Merbel 2008). A second option is to use a surrogate matrix such as stripped plasma wherein the 
endogenous levels have been removed using affinity adsorption, activated charcoal or some other 
means of removal (van de Merbel 2008). A third option is to use a substitute matrix such as a 
biological matrix from another species which does not produce the biomarker protein. Another 
option is to use a buffer as a surrogate matrix. Use of a surrogate matrix or substituted matrix 
avoids the need to continuously screen lots to identify low biomarker concentration matrices. A 
disadvantage is that additional studies will need to be carried out to demonstrate the absence of 
matrix effects. When using calibrators spiked with a surrogate matrix, it is essential to compare 
recovery to demonstrate that the concentration-response relationships are similar. Additionally, a 
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parallelism experiment is required to demonstrate that the endogenous biomarker behaves in a 
similar immunochemical manner to the reference standards (Lee, et al. 2006, Lee, et al. 2007, 
Lee, et al. 2009). 
1.3.3 Selectivity 
Selectivity is the ability of the method to determine the analyte unequivocally in the presence of 
components that may be expected to be present in the sample. During method development, 
selectivity is built into the method by choosing a unique signature peptide and choosing a SRM 
transition that has the least interference. As biomarkers are endogenous molecules, selectivity is 
evaluated by spiked recovery. To evaluate the selectivity, the basal level in individual lots is 
initially screened against a calibration standard curve obtained using calibrators prepared in a 
surrogate buffer matrix. The reference standard is then spiked in these lots to obtain a lower limit 
of quantification (LLOQ) concentration. At least 6 lots for each population are evaluated to 
account for inter-subject variability. Spiked recovery for each lot is estimated after accounting 
for baseline concentrations from the measured concentrations. The spiked recovery will have to 
be within a criterion set a-priori.   
1.3.4 Parallelism 
Parallelism is a dilutional linearity test of an authentic sample. This study demonstrates that the 
endogenous analyte in the unknown sample behaves similarly regardless of dilution by the 
standard matrix. Several individual samples, with high concentrations are chosen and analyzed 
undiluted and with a dilution factor of 3 or 4. The ratio of the calculated results (observed 
concentration x dilution factor) divided by the mean of the results are plotted against the inverse 
of the dilution factor. Parallelism is demonstrated if the ratio is not affected by dilution. If 
parallelism is cannot be established the method is only quasi-quantitative (Lee, et al. 2009). 
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1.3.5 Specificity 
Specificity is the ability of the method to distinguish between the analyte and other structurally 
similar molecules (Lee, et al. 2009). Cross-reactivity during immunoaffinity isolations during 
sample preparation, may result in a negative bias. If metabolites or isoforms of the biomarker 
protein are known and available as standards, a study can be designed to ensure that their 
presence does not have an  impact on protein biomarker  measurement.  
1.3.6 Accuracy, precision & assay range 
Many biomarker assays are developed to differentiate between healthy and diseased populations. 
A ‘fit-for-purpose’ assay range that covers baseline healthy individual concentrations as well as 
patient populations, is used. Additionally, dilution integrity should be established to enable 
analysis of unknown samples whose concentration falls above this assay range. 
Validation samples (calibration curve standards and quality control samples) are prepared using 
reference standards and used for measuring intra- and inter- assay accuracy and precision. 
Accuracy (expressed as percent deviation from normal (% DFN)) is the agreement between the 
measured result and its theoretical true value. Precision is a quantitative measure (usually 
expressed as %RSD and %CV) of the random variation between a series of measurements from 
the same homogenous sample. Usually different concentrations covering the assay range are 
prepared and used for validation studies.  Traditionally five levels are used : 1) LLOQ (2) lower 
quality control (LQC) which is approximately three times of LLOQ 3) Mid quality control 
(MQC) 4) High quality control (HQC) which is within 90% of the higher end of the assay range 
5) Dilution quality control (DQC) which is approximately 1.5 times the highest calibration 
standard. Accuracy and precision are assessed in multiple (at least 3) validation runs processed 
over different days. Each validation run is comprised of two sets of calibration curve standards 
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and six replicates of quality control samples. A predefined criterion is used for acceptance of 
accuracy and precision of the validation run.  The criteria used often range between those used 
for USFDA bioanalytical guidelines for small molecules and ligand binding assays (LBA) 
(Bower, et al. 2014, Lee 2009, Lee, et al. 2006, Stevenson, et al. 2013) 
1.3.7 Stability 
Stability of the analyte in stock solutions and the biological matrix should be demonstrated 
during validation. The analyte protein may undergo proteolytic cleavage or chemical (oxidation 
or aggregation) during storage. Usually freeze-thaw stability, bench-top stability, short and long 
term storage stability is established during validation. Incurred sample analysis may be 
performed to establish long term stability of patient samples. During sample collection, relevant 
inhibitors (protease inhibitor or platelet activation inhibitors) should be added, if degradation of 
the analyte protein or conversion of precursors is known (Ahmed 2009, Lee, et al. 2009, Zhu, et 
al. 2010).  
1.4 CONCLUDING REMARKS 
Immunoassays, primarily ELISAs, have dominated protein quantification over the last four 
decades. However, due to development in mass spectrometry over the last decade, this trend has 
started to shift. Mass spectrometry provides a universal platform for analysis of biomarker 
proteins. In addition to providing greater selectivity, ease of multiplexing and lower development 
cost, mass spectrometry based quantification of protein biomarkers has decreased biomarker 
assay development time, thus, enabling acceleration of the timeline between biomarker discovery 
and biomarker validation.  The use of sample preparation techniques such as ‘immunoaffinity 
isolations’ and ‘double extraction’ along with advancements in LC-MS/MS instrumentation has 
resulted in achieving detection limits comparable to those of ELISA.  
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Method development of mass spectrometry based biomarker assays involves a number of 
challenges including selection of signature peptides, selection and optimization of protein 
purification and digestion techniques and internal standardization. In recent years, there has been 
a lot of effort from regulatory authorities and industry to build consensus on development and 
validation of mass spectrometry based assays for proteins (Bower, et al. 2014, Sailstad, et al. 
2014, Stevenson, et al. 2013, van de Merbel, et al. 2014). With further advancements in mass 
spectrometric instrumentation, protein analysis software and sample preparation technology, 
biomarker bioanalysis will be more reliable, enabling more utility in clinical settings. Accurate 
and precise biomarker assays enable faster clinical decisions with regard to diagnosis and 
therapy selection. More reliable biomarker analysis will also promote higher acceptance of 
surrogate endpoint markers by regulatory authorities, allowing shorter clinical trials and shorter 
drug development time.  
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 CHAPTER 2 
 
 
2  DISSERTATION OBJECTIVES 
 
 
Mass spectrometry is being increasingly used in biomarker research mainly due its ability to 
achieve high selectivity coupled with high sensitivity (Makawita, et al. 2010, Ramanathan, et al. 
2011, Rauh 2012). This research proposal focuses on quantitative mass spectrometric 
investigations on protein biomarkers i.e. serum thymidine kinase 1 and human osteopontin 
(OPN). 
The first objective of this dissertation research will be to develop and validate a liquid 
chromatography and tandem mass spectrometry (LC-MS/MS) method to quantitatively measure   
the activity of thymidine kinase 1(TK1), a tumor biomarker,  in human serum. Thymidine kinase 
1 activity will be measured by monitoring the conversion of an exogenous TK1 substrate 3’-
fluorothymidine (FLT) to its phosphorylated product i.e. 3’deoxy-3’-fluorothymidine 
monophosphate (FLT-MP), using LC-MS/MS. The developed analytical method will be 
validated as per US FDA guidelines (Center for Drug Evaluation and Research (U.S.), et al. 
2001). Application of validated method will then be demonstrated by distinguishing TK1 activity 
in serum samples obtained from hepatocellular carcinoma patients along with matched controls. 
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Human osteopontin is secreted plasma protein which is elevated in various cancers and is 
indicative of poor prognosis (Rodrigues, et al. 2007). The second objective of this dissertation 
will involve development and validation of a capillary microflow LC-MS/MS method to quantify 
human osteopontin (hOPN) from plasma using a biologically relevant signature peptide. This 
method will use an immunopurification for isolation of hOPN from plasma. The isolated protein 
will then be digested with trypsin in the presence of an internal standard peptide to generate a 
biologically relevant signature peptide i.e. GDSVVYGLR. Preliminary studies showed that the 
peptide yields decreased with increased digestion time indicating signature peptide instability. A 
specific aim of this part of research would be the evaluation of a SIL peptide and an extended 
SIL peptide as internal standards to track digestion variability.  
The third research objective will be to develop an in vitro method for evaluating the 
cardiovascular risk potential of tobacco products by measuring the levels of secreted osteopontin 
and its metalloproteinase-3 (MMP-3) cleaved N-terminal fragment in the media of tobacco 
extract exposed endothelial cells. In order to achieve this objective, a method will be developed 
to simultaneously measure human osteopontin and its metalloproteinase-3 (MMP-3) cleaved N-
terminal fragment from cell culture media. 
The fourth objective of this dissertation will be to evaluate the use of peptide standards as 
internal standards to compensate for the immunocapture variability during LC-MS/MS 
quantification of a biomarker protein. We hypothesized that an extended SIL-IS peptide could be 
used to compensate for immunocapture variability during protein quantification provided that 
immunocapture is carried out with an antibody that binds to a common epitope present on both 
the protein and SIL-IS peptide. In this proof of concept investigation, we evaluate the ability of 
an extended SIL-IS peptide to compensate for immunocapture variability using a hOPN specific 
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antibody (MAB222P) that has an epitope in the signature peptide region (DSVVYG) of the 
protein. 
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 CHAPTER 3 
 
 
3 LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY METHOD 
FOR QUANTIFICATION OF THYMIDINE KINASE ACTIVITY IN HUMAN 
SERUM BY MONITORING THE CONVERSION OF 3’DEOXY-3’-
FLUOROTHYMIDINE TO 3’DEOXY-3’-FLUOROTHYMIDINE 
MONOPHOSPHATE. 
 
 
Drawn from published paper (Faria, et al. 2012) 
 
 
3.1  INTRODUCTION  
Thymidine kinase 1 (TK1, ATP; Thymidine 5’-phosphotransferase; EC.2.7.1.21) is a key cellular 
enzyme in DNA synthesis which catalyzes the one step pyrimidine salvage pathway (Bradshaw, 
et al. 1984).  Specifically, TK1 catalyzes the transfer of terminal phosphate from ATP to the 5’ 
hydroxyl group of deoxythymidine (dThd) to produce deoxythymidine monophosphate (dTMP). 
Increased activity of serum or plasma TK1 has been reported in diseases involving DNA 
metabolism, e.g., viral infections (Gronowitz, et al. 1984, Gronowitz, et al. 1986), vitamin B12 
deficiency (Gronowitz, et al. 1984) and in a variety of malignant diseases including acute and 
chronic leukemia(Hagberg, et al. 1985), Hodgkin’s disease (Eriksson, et al. 1985), non-
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Hodgkin’s lymphoma (Hallek, et al. 1992, Topolcan, et al. 2008) , lung cancer (Topolcan, et al. 
2008) and ovarian cancer (Hallek, et al. 1997, Topolcan, et al. 2008). TK1 also phosphorylates 
derivatives of thymidine or deoxyuridine (dUrd). In particular, TK1 can phosphorylate 
nucleotide analogs with modifications at the 5'-position of the  pyrimidine  ring, and the 3'-
position of the ribose including 5-fluoro-2’-dideoxythymidine and  3'-azido-3'-
deoxythymidine (Zidovudine) (Eriksson, et al. 1991, Furman, et al. 1986). These nucleotide 
analogs can therefore be used to monitor the activity of TK1 (Gronowitz, et al. 1984, Ohrvik, et 
al. 2004, Topolcan, et al. 2008). For example, 
18
F-3’deoxy-3’-fluorothymidine (18F-FLT), has 
been used to monitor tumor proliferation via positron emission tomography (Rasey, et al. 2002, 
Salskov, et al. 2007, Toyohara, et al. 2002). Phosphorylation of FLT by TK1 leads to cellular 
trapping and accumulation of FLT-monophosphate (FLT-MP) without incorporation into DNA. 
Since FLT has low affinity for TK2 in comparison with FLT-MP, it acts as a selective substrate 
to monitor TK1 activity (Eriksson, et al. 1991, Munch-Petersen, et al. 1991). 
Serum TK1 activity can reflect tumor burden and proliferation, and is most commonly measured  
using a commercially available thymidine kinase radioenzymatic assay (TK-REA), which uses 
125
I-deoxyuridine as a substrate to measure thymidine kinase 1 activity (Gronowitz, et al. 1984). 
This assay is time-consuming and requires radioactive waste management. A competitive 
enzyme-linked immunosorbent assay (ELISA) has also been used for measuring serum TK1 
activity for measuring phosphorylation of the selective TK1 substrate  3'-azido-2'-
deoxythymidine (AZT)   (Ohrvik, et al. 2004). Alternatively, 5-bromodeoxyuridine (BrdU) 
incorporation into DNA can be monitored by ELISA (Gronowitz 2007). After phosphorylation 
by TK1, bromodeoxyuridine monophosphate (BrdUMP) is processed to bromodeoxyuridine 
triphosphate (BrdUTP) by yeast enzymes, and the BrdUTP is immobilized by incorporation into 
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an immobilized DNA strand using a recombinant reverse transcriptase. Further, the amount of 
BrdUTP incorporated in DNA is estimated using an ELISA.  This assay is more sensitive than 
the assay using AZT as a substrate (Gronowitz 2007). However, complex sample processing, 
reagent expense, and selectivity issues associated with ELISA methods are limitations to its 
application.  
Quantification of nucleotide analogues can be performed using high performance liquid 
chromatography (HPLC) with ultraviolet or fluorescence detection (Jancita, et al. 1980, Serve, et 
al. 2010). In the last decade, mass spectrometric (MS) detection has increasingly been used for 
quantification of nucleoside and nucleotide analogs (Banoub, et al. 2005, Cohen, et al. 2009). 
Mass spectrometry allows extremely specific and sensitive quantification of nucleotide analogs 
from biological matrices including serum. Thus, LC-MS/MS can be used as a tool to measure the 
conversion of FLT to FLT-MP in serum.  
In our previous work, a method was developed to quantify the intracellular conversion of FLT to  
FLT-MP in cell lysates using LC-MS/MS (Li, et al. 2011b). Separation of the analytes was 
achieved using C18 column and detection using Applied Biosystems SCIEX API 4000 QTrap 
mass spectrometer. This method was able to monitor proliferating cell TK1 activity in as few as 
500 cells per well in LNCaP prostate cancer cells. In the present report, we describe the 
development and analytical validation of a suitable non-isotopic, non-immunologically based 
assay for quantitative monitoring of FLT to FLT-MP in human serum (See Figure 3-1). This 
method uses a labeled isotope internal standard, and column trapping to improve assay 
ruggedness.  
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Figure 3-1: Illustration showing the conversion of FLT to FLT-MP by thymidine kinase 1. 
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3.2 MATERIALS AND METHODS 
3.2.1 Chemicals and reagents 
HPLC grade acetonitrile and methanol were purchased from Honeywell Burdick & Jackson 
(Muskegon, MI, USA). 3’-Deoxy-3’fluorothymidine was purchased from Sigma Aldrich (St. 
Louis, MO, USA). 3’-Deoxy-3’fluorothymidine-5’-monophosphate disodium salt (FLT-MP), 3’-
Deoxy-3’fluorothymidine-d3 (FLT -d3) and 3’-Deoxy-3’fluorothymidine-5’-monophosphate-d3 
(FLT-MP-d3) were purchased from Toronto Research Chemicals Inc. (TRC, Toronto, ON, 
Canada). Citric acid, formic Acid, sodium acetate, adenosine 5’-triphosphate (ATP), uridine 5’-
monophosphate (UMP) , magnesium chloride (MgCl2) and dithioerythritol (DTE) were obtained 
from Sigma-Aldrich (St. Louis, MO, USA).  High purity water was obtained in-house using a 
NANOpure Diamond Life Science ultrapure water System from Barnstead International 
(Dubuque, IA, USA). Nitrogen was obtained from a Parker Balston Tri Gas Generator LCMS-
5000 (Haverhill, MA, USA). Microcentrifuge tubes (1.5ml) and disposable glass centrifuge 
(10ml) were purchased from VWR International (Westchester, PA, USA). Human serum was 
obtained from Biochemed Services, Inc. (Winchester, VA, USA). 
3.2.2 Instruments and HPLC conditions 
High performance liquid chromatography (HPLC) separations were performed using the 
following equipment: Shimadzu system controller SCL-10A VP, pumps LC-10AD VP, solvent 
degasser DGU14A (Shimadzu, Kyoto, Japan) and a Waters Acquity UPLC® system (Waters 
Corporation, Milford, USA).  Phenomenex Security Guard column (Gemini C18, 4× 2.0mm, 5 
μm) from Phenomenex (Torrance, CA, USA) was used as the loading column and an Aquasil 
C18 column (100mm×2.1mm I.D., 5 μm) from Thermo Scientific (Waltham, MA, USA) was 
used as the analytical column. The analytical column was maintained at 40°C. 
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Sample loading was achieved using a Waters Acquity UPLC® system. Pumps A and B delivered 
loading mobile phase A (0.1% formic acid) and loading mobile phase B (0.1% formic acid in 
acetonitrile), respectively. Sample loading was carried out with 100% loading mobile phase A 
maintained at a flow rate of 0.300 ml/min.  Following an initial loading time of 1.5 min, the 
diverter valve was switched to position B and the elution initiated.  A 10-port Cheminert 
switching valve and a microelectric actuator obtained from Valco Instruments Co. Inc. (Houston, 
TX, USA) was used to divert flow to the analytical column in position B.  After a running time 
of 5 minutes, the diverter valve position was switched back to allow flushing of the loading 
column.  The flushing of the loading column was carried out at 0.400ml/min with 50% loading 
mobile phase B.  After flushing for one minute, the loading mobile phase composition was 
changed back to 100% loading mobile phase A pumped at a flow rate of 0.300 ml/min.  Elution 
was carried out under gradient conditions using two Shimadzu pumps which were operated with 
a Shimadzu system controller. The elution mobile phases consisted of 0.1 % formic acid in water 
(A) and 0.1 % formic acid in acetonitrile (B).  The flow rate was set to 0.300 ml/min.  Gradient 
conditions were as follows: 0.0 –2.0 min, isocratic 5% B; 2.00 –4.0 min, linear from 5% to 75% 
B; 4.1 –7 minutes, isocratic 5% B.  The total running time was 7 minutes and the injection 
volume was 25 µL.  The column switching LC-MS/MS design is shown in Figure 3-2. 
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Figure 3-2: Column switching LC-MS/MS design 
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3.2.3 Mass Spectrometry conditions 
Mass spectra were obtained using an Applied Biosystems SCIEX API 4000 QTrap mass 
spectrometer operated in positive electrospray ionization mode (ESI).  Tuning and optimization 
of the mass spectrometer parameters were performed for the analytes and internal standard (IS, 
see below) by direct infusion of a 1 µg/mL standard solution at a flow rate of12 µL/min.  The 
multiple reaction monitoring (MRM) transitions, declustering potential (DP) entrance potential, 
collision energy (CE) and collision cell exit potential (CXP) for all the compounds are listed in 
Table 3-1.  The mass spectrometric parameters were as follows: ion source temperature 
(TEM=450°C), ion transfer voltage (IS=5500 V), collision gas (CAD=high), curtain gas 
(CUR=20), ion source gas 1 (GS1=55) and ion source gas 2 (GS2=45).  The units for gases are 
arbitrary. The data were acquired with Analyst software, Version 1.5.   
3.2.4 Preparation of stock solutions, standards and quality control samples 
Stock solutions were prepared by dissolving FLT and FLT-MP in methanol to yield 12.5 and 50 
µg/mL solutions, respectively.  Intermediate stock solutions were prepared by further diluting the 
stock solution in methanol to prepare spiked serum samples.  Internal standard stock solutions 
were prepared by dissolving FLT-d3 and FLT-MP-d3 in methanol to yield a concentration of 500 
μg/mL.  A working IS solution (final concentration of 200 ng/mL) was subsequently prepared by 
diluting the stock solutions of each compound in methanol. Stock solutions, QC solutions and IS 
solutions were stored at -20°C. 
3.2.5 Preparation of calibration standards and quality control samples in human serum 
Calibration standards and quality control samples were freshly prepared daily by spiking 
working solutions and quality control solutions in pooled human serum.  The concentration range 
of the calibration standards was FLT (0.500-500 ng/mL) and FLT-MP (2.5-2000 ng/mL).  The 
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quality control samples (Lower limit of quantification (LLOQ), Low quality control (LQC), 
Medium quality  control (MQC), High quality control (HQC) and dilution quality control ) had 
the following concentrations: FLT (0.50, 2.00, 40, 375 and 2000 ng/mL) and FLT-MP (2.50, 
6.00, 60, 1800 and 5000 ng/mL).  
3.2.6 Preparation of Phosphorylation Buffer and Reconstitution Solution 
Phosphorylation buffer was prepared fresh prior to sample analysis.  The buffer comprised 0.1 M 
sodium acetate, 7.8 mM ATP, 2 mM UMP, 12mM DTE and 30 mM MgCl2 in HPLC grade 
water.   Reconstitution solution was prepared by dissolving 19.2 mg of citric acid and 37.2 mg of 
EDTA in 100 ml HPLC grade water to obtain a mixture of 1mM Citric acid and 0.5 mM EDTA.  
This was used for reconstituting the samples prior to injection on to LC-MS/MS system. 
3.2.7 Sample preparation 
A 50 µl aliquot of serum (samples, calibration and quality control samples) was added to a1.5 ml 
microcentrifuge tube containing 50 µl of phosphorylation buffer solution. 10 µl of freshly 
prepared FLT (10 µg/ml), in phosphate buffered saline (PBS), was transferred to the 
microcentrifuge tubes containing serum samples, whereas 10 µl of PBS alone was transferred to 
the microcentrifuge tubes containing calibration standards and quality controls.  The samples 
were incubated for 2 hours at 37ºC in Labline Orbit Shaker Bath model 3540 (Melrose Park, 
ILIL, USA) at 125 rpm.  The reaction was terminated by addition of 300 µl of methanol to each 
tube.  The calibration standards and quality control samples were not incubated; instead the 
reaction was terminated immediately by addition of 300 µl of methanol to each tube.  To each 
tube, 50 µL of internal standard was added and the tube was vortex mixed for 2 minutes and 
centrifuged for 10 min. at 4ºC/10,000 rpm using an Eppendorf centrifuge model 5805 (Hamburg, 
Germany).  Approximately, 400 µL of supernatant was transferred into a 10 ml disposable glass 
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centrifuge tube and evaporated to dryness under nitrogen gas at 50°C for ~15minutes.  The 
samples were reconstituted with 50 µL of a reconstitution solution.  The reconstituted samples 
were transferred to a 1 mL 96-well plate and analyzed by LC-MS/MS. 
3.2.8 Matrix effects 
In order to evaluate matrix effects, a post-column infusion study was conducted.  A 100 ng/mL 
solution (FLT and FLT-MP) in methanol was prepared and continuously infused at 20 µL/min 
post HPLC column directly into the mass spectrometer using a “tee” connection.  After 
stabilization of the baseline, a blank sample was injected and the profiles were investigated for 
suppression or enhancement at the retention time of FLT and FLT-MP. 
3.2.9 Validation procedures 
Validation of the assay was performed according to the FDA guidelines for Bioanalytical 
Method Validation (Center for Drug Evaluation and Research (U.S.), et al. 2001).  Validations 
runs containing duplicate calibration standards, blank samples, and blank sample spiked with 
internal standard and replicates of QC samples were run on three separate days. 
3.2.9.1 Selectivity 
Human serum samples from six different sources were analyzed in duplicate along with spiked 
LLOQ serum calibration standards to evaluate selectivity of the analytical method.  Each 
individual lot was extracted according to the sample preparation procedure for calibration 
standards and quality control samples given above.  Selectivity requirements were that any peak 
area co-eluting at the retention time of analytes (FLT/FLT-MP) must be less than 20% of the 
peak area of the average of LLOQ samples for all six lots of blank serum samples.  Additionally, 
any peak area co-eluting at the retention time of internal standards (FLT-d3 and FLT-MP-d3) 
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must be less than 5% of the average peak area of the internal standard concentration for all six 
lots of blank serum samples. 
3.2.9.2 Linearity and LLOQ 
Eleven calibration standards were extracted in duplicate and analyzed in 3 independent runs.  
Calibration curves were fitted using linear regression of the ratio of the peak area response of the 
analyte and the internal standard versus concentration.  A weighting factor of 1/x
2
 was used for 
both the analytes (FLT and FLT-MP).  The acceptance criteria followed FDA guidelines for 
bioanalytical method validation [22]. 
3.2.9.3 Accuracy and precision 
Accuracy and precision were determined from QC samples (LQC, MQC, HQC, dilution QC) in 
three independent runs.  A criterion of ±15% of the nominal concentration was used to assess 
accuracy and precision was expressed as %RSD, which should not exceed ±15%.  Intra-assay 
precision and accuracy were determined from 6 replicates of each QC sample on a single assay.  
Inter-assay precision and accuracy were determined by analyzing three different validation runs.  
3.2.9.4 Recovery and carryover 
Analyte recovery of the extraction procedure was determined by comparing peak areas.  Blank 
serum was spiked with FLT and FLT-MP at two levels (LQC and HQC).  These samples were 
compared to samples spiked after extraction with the same final concentrations of FLT and FLT-
MP to compensate for variations in instrument response.  The criterion for acceptance in this 
recovery experiment was that recovery was consistent over the two QC levels.  Carry over was 
assessed by injecting LQC immediately after each of the highest calibration standards in an 
analytical run.  The acceptance criterion for this experiment was that the LQC must be accurate 
to within 15% of the nominal concentrations. 
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3.2.9.5 Stability Studies 
Post-preparative stability was assessed using blank serum samples spiked with FLT and FLT-MP 
at two levels LQC and HQC.  These quality control samples were processed and maintained at 
5°C in the autosampler.  After 48 hours, these samples were analyzed against a freshly spiked 
calibration standard curve.  A criterion of ±20% of the nominal concentration was used to assess 
for 48 hours post-preparative stability.  Additionally, the intermediate stability of samples, i.e. 
supernatant, was assessed.  Spiked serum LQC and HQC samples of FLT and FLT-MP were 
processed as described above.  The supernatant (400 μl), obtained after protein precipitation and 
vortex mixing, was transferred to a 10 ml disposable glass centrifuge tube, then stored at  4°C.  
After 48 hours, the supernatant was processed and analyzed against a freshly spiked calibration 
standard curve.  A criterion of ±20% of the nominal concentration was used for intermediate 
stability. 
3.2.9.6 Precision of the FLT Phosphorylation reaction 
In order to assess the precision of the phosphorylation procedure, a serum sample having high 
TK1 activity (serum H) was diluted with a serum sample having low TK1 activity (serum L)  to 
obtain six different control concentrations as follows : 1) Undiluted serum H  2) Serum H diluted 
2 times with serum L 3) Serum H diluted 5 times with serum L 4) Serum H diluted 10 times with 
serum L 5) Serum H diluted 25 times with serum L 6) Undiluted serum L.  Six replicates were 
analyzed and assay precision was expressed as %RSD for each control concentration.  The serum 
sample with high TK1 activity (serum H) was defined arbitrarily to have an activity equivalent to 
1 while the serum sample having low TK1 activity (serum L) was defined as an activity 
equivalent to 0.  Activity units for the six levels were calculated based on the ratio of the activity 
  
45 
 
of serum H to serum L.  These activity units were used to correlate TK1 with the amount of FLT-
MP generated at the end of 2 hour incubation at 37°C 
3.2.10 Application of the validated method  
The validated method was used for determination of TK1 activity in 19 serum samples obtained 
from hepatocellular carcinoma patients and 40 healthy, age-matched controls (20 male and 20 
female; Bioreclamation Inc., Westbury, NY, USA).     
 
3.3 RESULTS AND DISCUSSION 
This serum TK1 activity assay monitors the phosphorylation of FLT, a thymidine analog and 
selective TK1 substrate, to its metabolite FLT-MP. The reaction is performed at 37°C in a 0.1M 
sodium acetate phosphorylation buffer supplemented with enzyme co-factors and stabilizing 
reagents (Karlstrom, et al. 1990, Ohrvik, et al. 2004). ATP serves as a phosphate donor in the 
reaction. The reducing agent DTE liberates TK1 from inhibitory serum protein complexes, and 
UMP serves as a FLT-MP degradation inhibitor [11]. The FLT phosphorylation FLT 
phosphorylation reaction is terminated by methanol extraction. Calibration and quality control 
standards were freshly prepared to avoid analyte degradation in human serum that can occur after 
extended storage [11]. Since recombinantly produced TK1, and TK1 generated from cell lysates 
may not be biochemically representative of TK1, serum with high endogenous TK1 activity was 
diluted with low-activity serum to serve as positive controls (Rasey, et al. 2002, Salskov, et al. 
2007). Target analytes were extracted using protein precipitation, and chromatographically 
separated using a column switching strategy.  Specifically, samples were loaded onto a C18 
Phenomenex security guard column, which retains the analytes while impurities were eluted to 
waste. After column switching, analytes were separated on an Aquasil C18 analytical column 
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and detected using the QTrap in MRM mode.  Without column switching, a build-up of matrix 
on the column after multiple injections was observed, which resulted in a loss of sensitivity (data 
not shown).       
LC-MS/MS conditions were optimized for the analytes (FLT, FLT-MP, FLT-d3 and FLT-MP-
d3), allowing their quantification with a total run time of 7 min.  Retention times and mass 
transitions are shown in Table 3-1. Representative chromatograms of blank samples for FLT and 
FLT-MP are shown in Figure 3-3 and 3-4, respectively. Representative chromatograms of FLT 
and FLT-MP at the LLOQ are shown in Figure 3-5 and 3-6, respectively.  Matrix effects were 
evaluated with post-column infusion of a 100 ng/mL FLT and FLT-MP solution. No suppression 
or enhancement was seen at retention time of analyte peaks. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
47 
 
Table 3-1:Mass Spectrometer Parameters and Approximate Retention Times 
Analyte Retention 
Time 
(mins) 
Multiple Reaction 
Monitoring Transitions 
 (Parent ion → Product 
ion) 
DP 
( Volts) 
EP 
( Volts) 
CE 
( Volts) 
CXP 
( Volts) 
FLT 3.95 245.1 → 127.1 40 10 20 10 
FLT-d3 3.95 248.0 → 130.2 40 10 20 10 
FLT-MP 3.53 325.3 → 81.2 50 10 28 10 
FLT-MP-d3 3.53 328.1 → 81.2 50 10 28 10 
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Figure 3-3: Representative chromatogram of serum blank (FLT and FLT-d3) 
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Figure 3-4: Representative chromatogram of serum blank (FLT-MP and FLT-MP-d3). 
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Figure 3-5 : Representative chromatogram of Lower limit of Quantification(LLOQ) of FLT 
and FLT-d3. 
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Figure 3-6 : Representative chromatogram of Lower limit of Quantification(LLOQ)  of FLT-
MP (LLOQ) and FLT-MP-d3 
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3.3.1 Validation of the analytical method 
3.3.1.1 Selectivity 
The peak area at the retention time for all the analytes in the six human serum lots was found to 
be less than 10% of the respective LLOQ serum calibration standard.  Thus, indicating that the 
method was selective estimating FLT and FLT-MP from human serum samples.  
3.3.1.2 Linearity 
The peak area ratio of FLT to FLT-d3 and FLT-MP to FLT-MP-d3 were linear over the range 
0.5-500 ng/mL and 2.5-2000 ng/mL, respectively.  The calibration curves yielded a mean 
correlation coefficient of 0.9964 and 0.9935 for FLT and FLT-MP, respectively (n=3).  A 
weighting factor of 1/x
2
 was used for both analytes (FLT and FLT-MP). The back calculated 
concentrations of the calibration curve standards in the validation runs are summarized in Table 
3-2 and 3-3.   The percent deviation from nominal (%DFN) for the mean back-calculated values 
of the calibration standards were between -14.7% and 11.7% for FLT and -4.3% to 7.5% for 
FLT-MP.  Precision of the calibration standards, measured as the percent relative standard 
deviation for the mean back-calculated values, ranged between 6.0% to 13.4% for FLT and 3.5% 
to 14.1% for FLT-MP. 
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Table 3-2: Summary of back calculated concentrations of FLT calibration curve standards 
 
FLT (ng/mL) 
RUN 0.50 1.00 2.50 5.00 10.0 25.0 50.0 100 250 400 500 
Validation Run 1 0.402 A 1.85 4.96 12.5 27.2 60.8 101 226 386 431 
 
A 0.85 2.58 4.86 10.3 23.9 50.4 92 246 434 A 
Validation Run 2 0.459 0.96 2.15 4.75 10.3 27.3 53.2 89 217 317 399 
 
0.443 0.86 2.45 5.71 10.9 27.5 52.7 107 273 413 451 
Validation Run 3 A 0.718 2.37 4.85 11.5 24.4 50.7 89 230 A 485 
 
0.42 0.875 2.73 5.60 11.5 27.3 55.7 113 A 384 523 
Mean 0.43 0.85 2.36 5.12 11.2 26 54 98 238 387 458 
StdDev 0.03 0.09 0.32 0.42 0.8 1.7 3.9 10.2 22 44 47.99 
%RSD 6.0 10.3 13.4 8.2 7.6 6.3 7.2 10.4 9.2 11.4 10.5 
%DFN -14.0 -14.7 -5.8 2.4 11.7 5.1 7.8 -1.6 -4.6 -3.3 -8.4 
A = deleted from calculations per SOP criteria of ± 15% (20% for LOQ) 
 
 
 
 
 
 
 
 
 
  
54 
 
Table 3-3: Summary of back calculated concentrations of FLT-MP calibration curve 
standards 
 
FLT-MP(ng/mL) 
RUN 2.50 5.00 10.0 25.0 50.0 100 250 500 1000 1850 2000 
Validation Run 1 2.38 4.32 9.05 21.8 52.2 93.4 265 499 973 1810 1990 
 
A 5.45 10.5 27.0 49.5 109 246 552 1070 1890 1900 
Validation Run 2 2.62 4.34 8 22.9 51.5 107 267 564 1040 1900 2010 
 
2.60 4.94 11.1 26 52.4 109 252 561 937 1730 1920 
Validation Run 3 2.96 5.05 9.13 24.9 41.5 87.9 241 494 1360 1610 1830 
 
2.88 5.07 10.5 25.4 51.4 88.1 232 466 1030 1680 1890 
Mean 2.69 4.86 9.7 24.7 49.8 99 251 523 1068 1770 1923 
StdDev 0.23 0.45 1.2 2.0 4.2 10.4 14 42 151 117 67 
%RSD 8.7 9.2 12.1 7.9 8.4 10.5 5.5 7.9 14.1 6.6 3.5 
%DFN 7.5 -2.8 -2.9 -1.3 -0.5 -0.9 0.2 4.5 4.5 -4.3 -4.3 
A = deleted from calculations per SOP criteria of ± 15% (20% for LOQ) 
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3.3.1.3 Accuracy and Precision 
The lower limit of quantification (LLOQ) was established at 0.5 ng/mL for FLT with a precision 
of 8.8%.  The LLOQ for FLT-MP was set at 2.5 ng/mL with a precision of 11.5%.  Accuracy at 
the LLOQ was -9.2% and -3.8% for FLT and FLT-MP, respectively. Inter- and intra-assay 
precision and accuracy for FLT and FLT-MP quality control samples are shown in Table 3-4. 
3.3.1.4 Extraction recovery and Carryover studies 
The mean extraction recovery for FLT in human serum, determined at the LQC and HQC levels, 
was 103.5% and 100.3%, respectively.  FLT-MP mean extraction recovery was 57.0% and 
56.9% for LQC and HQC, respectively.  
All the LQCs were within 15% of the nominal concentrations when injected after a high 
calibration standard for both analytes (FLT and FLT-MP). Thus, illustrating that carryover is not 
significant for this method.   
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Table 3-4: Inter-assay and Intra-assay precision and accuracy for FLT and FLT-MP. 
 
Nominal Concentration (ng/mL) 
 2.0 40.0 375 2000 
Observed FLT Concentration 
(ng/mL) 
    Inter-assay mean ± SD 2.0±0.2 40.0±5.9 377.0±39.0 1830.0±84.0
Inter-assay precision (%RSD) 9.4 14.9 10.4 4.6 
Inter-assay accuracy (%DFN) -0.2 -1.1 0.4 -8.5 
     Intra-assay mean ± SD (n= 6) 2.1±0.2 45.0±2.6 378.0±14.0 1797.0±50.0
Intra-assay precision (%RSD) 7.7 5.9 3.6 2.8 
Intra-assay accuracy (%DFN) 3.5 11.6 0.9 -10.2 
     6.0 60.0 1800.0 5000.0
Observed FLT-MP Concentration 
(ng/mL)     
Inter-assay mean ± SD 6.6±1.0 65.0±5.7 
1939.0±95.
0 
5159.0±342.
0 
Inter-assay precision (%RSD) 14.6 8.8 4.9 6.6 
Inter-assay accuracy (%DFN) 9.4 7.8 7.7 3.2 
     
Intra-assay mean ± SD (n =6) 6.7±0.3 66.0±2.5 
1958.0±64.
0 
5275.0±304.
0 
Intra-assay precision (%RSD) 4.4 3.7 3.3 5.8 
Intra-assay accuracy (%DFN) 11.8 10.4 8.8 5.5 
SD = Standard Deviation, %DFN = percent deviation from nominal value, %RSD = percent 
relative standard deviation. Samples were diluted 10-fold for the FLT (2000 ng/mL) and FLT-
MP (5000 ng/mL) controls. 
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3.3.1.5 Post preparative stability 
For FLT, %DFN for the mean back-calculated values of the quality control standards were 
between -20.0% and -10.2% for LQC and -10.5% to -5.5% for HQC.  For FLT-MP, %DFN for 
the mean back-calculated values of the quality control standards were between -9.3% and -6.3% 
for LQC and 1.5% to 2.8% for HQC. Thus, post-preparative stability was found to be within the 
acceptance criteria. 
3.3.1.6 Intermediate processing stability 
For FLT, %DFN for the mean back-calculated values of the quality control standards were 
between -14.6% and -13.2% for LQC and -2.0% to -3.0% for HQC.  For FLT-MP, %DFN for 
the mean back-calculated values of the quality control standards were between -13.1% and -8.6% 
for LQC and 19.0% to 9.0% for HQC.  Thus, the supernatant obtained during processing was 
considered stable within specifications when stored at 4°C for 48 hours. 
3.3.1.7 Precision of the FLT phosphorylation reaction 
Phosphorylation reaction precision (% RSD) was within 15% at all concentrations except the 
defined zero level (Table 3-5). Additionally, the average concentration of FLT-MP in these 
samples and TK1 activity were found to have a positive linear correlation with a correlation 
coefficient of 0.9862 (See Figure 3-7).  
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Table 3-5: Precision of the FLT phosphorylation reaction. 
  
Enzyme 
Level-1                                 
Enzyme 
Level-2         
Enzyme 
Level-3                     
Enzyme 
Level-4                     
Enzyme 
Level-5                    
Enzyme 
Level-6 
TK1 Activity Units* 1.00 0.50 0.20 0.10 0.04 0.00 
 Average concentration 
of FLT-MP  (ng/ml)** 
965.33 599.80 245.80 131.83 58.05 5.09 
SD 34.915 60.726 32.980 14.662 4.972 1.273 
%CV 3.62 10.12 13.42 11.12 8.56 25.03 
 
* The serum sample with high TK1 activity (serum H) was defined arbitrarily to have an activity 
equivalent to 1 while the serum sample having low TK1 activity (serum L) was defined as an 
activity equivalent to 0.  Activity units for the six levels were calculated based on the ratio of the 
activity of serum H to serum L. ** The FLT-MP concentrations were generated under 
standardized conditions of 2 hour incubation at 37°C. 
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Figure 3-7: Plot of average FLT-MP concentration formed versus TK1 activity. 
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3.3.2 Application of the method to patient samples 
Average FLT-MP generation in serum from healthy male and female volunteers aged 50 or older 
was 19.1±10.5 ng/ml and 18.7±5.8 ng/ml, respectively when analyzed using the standardized 
reaction conditions described here (37
◦
 C, 2 hours).  
The average FLT-MP concentration in healthy individuals was 18.9 ± 8.5 ng/ml.   In contrast, the 
hepatocellular carcinoma patient serum samples showed a relatively wide variation in TK1 
activity as seen by the varying of FLT-MP concentrations (11.7-1350.5 ng/ml). A comparison of 
FLT-MP concentrations between the hepatocellular carcinoma (HCC) patient samples and the 
matched controls is seen in Figure 3-8. From this figure, it can been seen that a sub-population of 
the HCC patient samples demonstrated almost a  20 fold increase in TK1 activity. The increased 
TK1 activity in the HCC sub-patient population may have been due to differences in the severity 
of their disease although this could not be verified since detailed information regarding these 
samples was not available.  
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Figure 3-8:Comparison of serum TK1 activity in hepatocellular carcinoma (HCC) patient 
samples & matched controls. 
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3.4 CONCLUSIONS 
Serum TK1 activity is a potentially useful biomarker for monitoring haematological 
malignancies and solid tumors. A sensitive, non-radiometric LC-MS/MS assay for was 
developed and validated for monitoring the conversion of FLT to FLT-MP in human serum.  
Based on established, radiometric TK1 activity assays, this novel method shows good linearity 
and selectivity in human serum samples. Stability studies demonstrated adequate intermediate 
processing and post-preparative analyte stability.  
The applicability of the method for measuring serum TK1 activity was demonstrated in 
hepatocellular carcinoma patient serum samples and age-matched control sera. Significantly 
higher concentrations of FLT-MP were found in 26.3% of the hepatocellular carcinoma patient 
samples in comparison with controls.  This method is proposed as an alternative to ELISA and 
radio-enzymatic assays for rapid and selective determination of serum TK1 activity. 
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CHAPTER 4 
 
 
4 COMPARISON OF A STABLE ISOTOPE LABELED (SIL) PEPTIDE AND AN 
EXTENDED SIL PEPTIDE AS INTERNAL STANDARDS TO TRACK DIGESTION 
VARIABILITY OF AN UNSTABLE SIGNATURE PEPTIDE DURING 
QUANTIFICATION OF A CANCER BIOMARKER, HUMAN OSTEOPONTIN, 
FROM PLASMA USING CAPILLARY MICROFLOW LC-MS/MS. 
 
 
Drawn from manuscript submitted to J. Chromatography B., June 2014 
 
 
4.1 INTRODUCTION 
Human osteopontin (hOPN) is a matricellular protein that mediates diverse biological functions 
(Lund, et al. 2009). It is involved in normal physiological processes and is implicated in the 
pathogenesis of a variety of disease states, including atherosclerosis, cancer, and several chronic 
inflammatory diseases (Lund, et al. 2009, Rodrigues, et al. 2007, Waller, et al. 2010). It is 
reported to play a major role in tumor promotion mechanisms including cell survival, adhesion, 
migration, invasion and angiogenesis (Rodrigues, et al. 2007). Over expression of hOPN has 
been found in a variety of cancers, including breast cancer, lung cancer, colorectal cancer, 
stomach cancer and ovarian cancer (Rodrigues, et al. 2007). It is also secreted in serum, plasma, 
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urine and other body fluids. Elevated plasma OPN levels have been associated with poor survival 
in cancer patients (Rodrigues, et al. 2007). OPN primarily operates by binding to various 
integrins mainly through its RGD (arginine-glycine-aspartic acid) amino acid sequence. 
Integrins are transmembrane receptors that mediate attachment between a cell and its 
surroundings. The adhesive RGD domain of OPN mediates interactions via αvβ1, αvβ3, αvβ5, 
αvβ6, α8β1, and α5β1 integrins (Shimada, et al. 2005).  OPN can be cleaved by thrombin near its 
RGD integrin binding domain to expose a cryptic SVVYGLR amino acid sequence that can bind 
to α9β1, α4β1, and α4β7 integrins (Scatena, et al. 2007). Furthermore, the cryptic site can be 
further cleaved by metallomatrix proteinases (MMPs) at the glycine-lysine (
167
G-L) bond and by 
plasma carboxypeptidase B-2 (CPB-2) at the (
168
L-R) bond. The impact of proteolytic 
modification of OPN can promote or disrupt integrin binding, leading to altered cellular 
responses (Scatena, et al. 2007, Shimada, et al. 2005) . 
Immunoassays, in particular, enzyme linked immuno-sorbent assay (ELISA), have been the 
method traditionally used for analysis of protein biomarkers. However, immunoassay 
measurements can be variable and inaccurate due to cross-reactivity of the antibodies used, the 
presence of post-translational modifications, interference due to autoantibodies and anti-reagent 
antibodies, and the high-dose hook effect (Hoofnagle, et al. 2009). Different commercially 
available ELISA kits for quantification of OPN have been shown to yield variable and non-
comparable absolute concentrations (Anborgh, et al. 2009, Plumer, et al. 2008, Vordermark, et 
al. 2006). For example, Plummer et al. compared three ELISA kits which produced >20-fold 
differences in measured absolute hOPN concentrations for the same sample. Such variations can 
lead to misleading interpretations resulting in unnecessary treatment or missed opportunities for 
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therapeutic intervention. We therefore decided to explore an alternative platform for measuring 
hOPN from plasma.  
In the last decade, tandem mass spectrometry using selected reaction monitoring (SRM) is 
increasingly employed for analysis of biomarker proteins (Makawita, et al. 2010).  Due to the 
limited mass range of most mass analyzers used for quantification, LC-MS/MS protein 
quantification often involves digestion of the protein to yield peptides, including unique 
signature peptides, which are then quantified along with an appropriate internal standard. Thus, 
protein quantification involves a number of challenges including signature peptide selection, 
protein digestion, sample enrichment and internal standardization (Makawita, et al. 2010). 
The identification and selection of an appropriate signature peptide is an important aspect 
method development, as the signature peptide serves as a surrogate analyte for the protein. 
Utilizing the protein’s peptide map or amino acid sequence, in-silico proteolytic digestions can 
be carried out using software such as Skyline software and Protein Prospector, and proteotypic 
peptides can be identified using Basic Local Alignment Search Tool (BLAST) (Becker, et al. 
2011, Halquist, et al. 2011b, Luna, et al. 2008, Rauh 2012). 
Protein biomarker measurements are usually made from tissues or blood fractions i.e. plasma or 
serum. Since blood measurements are less invasive, they are preferred over tissue measurements. 
However, plasma and serum are highly complex biological fluids. In fact, in serum, 20% of 
proteins comprise 99% of total protein content and the concentrations of all proteins span more 
than 12 orders of magnitude (Makawita, et al. 2010). Analysis of direct digests of serum or 
plasma would be ideal since it would involve minimal sample preparation. However, matrix 
effects and interferences from other highly abundant proteins may adversely affect the limit of 
quantification and selectivity of these mass spectrometric methods (Makawita, et al. 2010). Thus, 
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sample enrichment is an essential part of most protein quantification methods. Sample 
preparation for protein purification from a biological matrix prior to quantification using LC-
MS/MS can be categorized into three major strategies i.e. abundant protein removal, 
immunoaffinity  protein isolation and immunoaffinity signature peptide isolation after digestion 
(Ackermann, et al. 2007). Depending on the level of purification required, one of the above 
strategies or a combination of these could be used. For high and mid-abundance plasma proteins 
(>100 ng/ml), abundant protein removal may be adequate for quantification (Ackermann, et al. 
2007). However, quantification of low abundance (< 100 ng/ml) proteins would likely require 
the use of immunoaffinity isolation. 
Another important challenge in mass spectrometric protein quantification is the choice of an 
appropriate internal standard (IS). An ideal IS should mimic the properties of the analyte in all 
sample preparation and analysis steps. In LC-MS/MS quantifications, an IS accounts for any 
losses during sample preparation as well as minimizes the effects of response fluctuations on the 
mass spectrometer. During mass spectrometric quantification, a response ratio of the analyte and 
the internal standard is correlated with the concentration ratio of the analyte and the internal 
standard (Bronsema, et al. 2012).  
For quantification of small molecules using LC-MS/MS, a stable-isotope labeled (SIL) form of 
the analyte or a structural analogue can be used as an IS. However, since protein quantification 
involves protein digestion, there are more options for internal standardization. A SIL form or a 
structural analogue of either the intact protein or the signature peptide can be used. Alternatively, 
an extended SIL-peptide, which can be cleaved to obtain SIL signature peptides, can be used as 
an IS. A SIL-protein may be an ideal IS for protein quantification. However, SIL-proteins are 
very difficult to obtain because they require specific folding of the linear amino acid sequence, as 
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well as creation of intra-molecular disulfide linkages and post-translational modification. A 
method known as SILAC (Stable Isotope Labeling with Amino Acids in Culture) can be used to 
generate SIL-proteins(Ong, et al. 2002). However, the production of SIL-proteins can be limited 
by cost and commercial availability (Bronsema, et al. 2012). A more commonly used internal 
standard for protein quantification is a SIL-peptide with the same aminoacid sequence as the 
signature peptide.  A SIL-peptide is normally added following protein enrichment and prior to 
digestion. It does not compensate for digestion variability but does account for subsequent 
peptide analyte recovery and potential ion suppression effects (Ackermann, et al. 2007). An 
extended or “winged” SIL-peptide, however (containing additional amino acid residues on one 
or both ends), would be able to also track digestion, provided it is cleaved at the same rate as the 
signature peptide (Bronsema, et al. 2012). In sample preparation methods involving peptide 
immunoaffinity isolations, an extended SIL-peptide IS would also able to track variability and 
recovery during immunocapture (Ocana, et al.). 
Recently, Wu et al (2012), quantified OPN splice variants from plasma of lung cancer patients 
using a combination of four OPN specific antibodies for IA protein isolation coupled with 
targeted mass spectrometry (Wu, et al. 2012). However, the validation of the method was not 
reported. In addition, the method used signature peptides which are reported to undergo post 
translational phosphorylation. 
Most LC–MS/MS bioanalytical assays are performed with conventional HPLC separations, 
using 2.1-4.6 mm ID columns and chromatographic flow rates of 300–1000 μL/min, and mass 
spectrometric detection using triple quadrupole instrument operating in electrospray ionization 
(ESI) mode. The benefits of using microflow liquid chromatography (MFLC) were realized in 
the 1970s; however, reliable hardware that meets regulated bioanalysis standards were not 
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available (Arnold, et al. 2013). In recent years, accurate pumps delivering nanoflow and 
microflow rates, reliable lower internal diameter columns, and improvements in nanospray ion 
sources have facilitated the use of MFLC-MS/MS platforms for quantitative bioanalysis. Use of 
microflow LC-MS/MS platforms (flow rate < 3 μL/min) using columns with internal diameters 
less than 1 mm have resulted in increased sensitivity, reduction in sample volume and solvent 
consumption (Arnold, et al. 2013, Broccardo, et al. 2013, Christianson, et al. 2013, Dijksman, et 
al. 2012, He, et al. 2012, McAvoy, et al. 2014, Wang, et al. 2013, Zhou, et al. 2013). 
In this paper, we describe the development and validation of a method to quantify hOPN from 
plasma using a capillary microflow LC-MS/MS system. A schematic diagram of the strategy 
used for osteopontin quantification with LC-MS/MS using immunoaffinity isolation is given in 
Figure 4-1. The method uses immunopurification for isolation of hOPN from plasma. The 
isolated protein is then digested with trypsin in the presence of an internal standard peptide to 
generate a biologically relevant signature peptide i.e. GDSVVYGLR. Peptide yields decreased 
with increased digestion time indicating signature peptide instability. A SIL peptide and an 
extended SIL peptide were evaluated as internal standards to track digestion variability. The 
signature peptide is quantified using a Waters nanoAcquity/TRIZAIC-Xevo-TQS LC-MS/MS 
system.  
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Figure 4-1:A schematic diagram of  the strategy used for osteopontin quantification using LC-
MS/MS and immunoaffinity isolation. 
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4.2 MATERIALS AND METHODS 
4.2.1 Reference Materials 
Recombinant hOPN was purchased from R&D Systems (Minneapolis, MN, USA). The OPN 
signature peptide (OPN-SP), having the amino acid sequence ‘GDSVVYGLR’, was synthesized 
by Elim Biopharmaceuticals (Hayward, CA, USA). A stable isotope labeled peptide having the 
sequence ‘GDSVVYGLR*’, containing an arginine residue labeled with 13C and 15N4 was 
synthesized by Thermo Scientific (Rockford, IL, USA) and used as the SIL-IS. The labeled 
arginine residue resulted in a mass shift of +10 Da from the mass of the OPN-SP. Another stable 
isotope labeled peptide having the sequence ‘TYDGRGDSVV*YGLRSKSKKF’, containing an 
valine residue labeled with 
13
C and 
15
N4 was synthesized by Thermo Scientific (Rockford, IL, 
USA) and used as an extended SIL-IS. The labeled valine residue resulted in a mass shift of +6 
Da from the mass of OPN-SP.  
4.2.2 Reagents 
HPLC grade water with 0.1% formic acid and acetonitrile with 0.1% formic acid were purchased 
from Honeywell Burdick & Jackson (Muskegon, MI, USA). High grade water was obtained 
using a Milli-Q integral water purification system (Billerica, MA, USA). Bovine serum albumin, 
dulbecco’s phosphate buffered saline, formic acid, methanol, Trizma hydrochloride (1M) and 
tween 20 were purchased from Sigma-Aldrich (Saint Louis, MO, USA). Glacial acetic acid was 
obtained from Macron Fine Chemicals (Center Valley, PA, USA). Sodium chloride solution 
(5M) and EDTA solution  (0.5M) were obtained from Ambion (Foster City CA, USA). Trypsin 
Gold was obtained from Promega (Madison, WI, USA). Biotinylated antibodies specific to 
hOPN (MAB193P) were obtained as a gift from Maine Biotechnology Services (Portland, 
Maine, USA).  Immuno-capture (IC) buffer and IC wash buffer were prepared in-house and were 
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comprised of 0.1/5.0/3.0/0.2/91.7/0.1 (v//v/v/v/w) Tween 20/ Trizma HCl (1M)/ NaCl 
(5M)/EDTA (0.5M)/water/ bovine serum albumin and 5.0/3.0/0.2/91.8/0.1 (v/v/v/v) Trizma HCl 
(1M)/ NaCl (5M)/ EDTA (0.5M)/ water, respectively. Digestion solution, containing of 500 
ng/100 µL of trypsin gold,  0.05 pg/100 µL of SIL-IS peptide and 0.68 pg/100 µL of extended 
SIL-IS peptide in 50 mM ammonium bicarbonate buffer, was freshly prepared prior to digestion 
for the validation studies. 
4.2.3 LC-MS/MS Instrumentation 
Preliminary method development studies were carried out using a conventional flow LC-MS/MS 
system. The method was then transferred and validated on a MFLC-MS/MS. 
4.2.3.1 Conventional flow LC-MS/MS system 
High performance liquid chromatography (HPLC) separations were performed using the 
following equipment: Shimadzu system controller SCL-10A VP, pumps LC-10AD VP, solvent 
degasser DGU14A (Shimadzu, Kyoto, Japan) and a Waters Acquity UPLC
® 
system (Waters 
Corporation, Milford, USA). ACE HPLC C4 column (50mm × 2.1 mm I.D., 5 μm) from 
Advanced Chromatography Technologies Ltd, (Aberdeen, Scotland) was used as the trap column 
and a Peptide Separation Technology (PST) XBridge BEH C18 column (100mm × 2.1mm I.D., 
5 μm) from Waters (Milford, USA) was used as the analytical column. The analytical column 
was maintained at 50°C. 
Trapping was achieved using a Waters Acquity UPLC
®
 system using trap mobile phase A 
(HPLC grade water with 0.1% formic acid) and trap mobile phase B (acetonitrile with 0.1% 
formic acid), respectively. Trapping was carried out with 5% trap mobile phase B and 
maintained at a flow rate of 0.300 mL/min. Following an initial trapping time of 0.8 min, the 
diverter valve was switched to position B and the elution initiated. A 10-port Cheminert 
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switching valve and a microelectric actuator obtained from Valco Instruments Co. Inc. (Houston, 
TX, USA) was used to divert flow to the analytical column in position B. After a running time of 
4.5 minutes, the diverter valve position was switched back and flushing of the trap column was 
achieved at 0.300 mL/min with 5% trap mobile phase B. Elution was carried out using two 
Shimadzu pumps operated with the Shimadzu system controller to apply the gradient conditions 
and the elution mobile phases consisted of water with 0.1% formic acid (A) and acetonitrile with 
0.1% formic acid (B). The flow rate was set to 0.400 mL/min. Gradient conditions were as 
follows: 0.0 –1.0 min, isocratic 5% B; 2.0 –4.0 min, linear from 5% to 30% B; 4.0 –4.5 min, 
linear from 30% to 80% B; 4.5 –5.0 min, isocratic 5% B. The total running time was 5 min and 
the injection volume was 25 µL. The LC-MS/MS setup is illustrated in Figure 4-2. 
Mass spectra were obtained using an Applied Biosystems SCIEX API 4000 QTrap Mass 
Spectrometer operated in positive electrospray ionization mode (ESI).  Tuning and optimization 
of the mass spectrometer parameters were performed for the analytes and internal standard (IS, 
see below) by direct infusion of a 1 µg/mL standard solution at a flow rate of 12 µL/min. The 
multiple reaction monitoring (MRM) transitions, declustering potential (DP) entrance potential, 
collision energy (CE) and collision cell exit potential (CXP) for all the compound are listed in 
Table 4-1. The mass spectrometric parameters were as follows: ion source temperature 
(TEM=450°C), ion transfer voltage (IS=5500 V), collision gas (CAD=high), curtain gas 
(CUR=10), ion source gas 1 (GS1=30), ion source gas 2 (GS2=20), declustering potential 
(DP=60 V), entrance potential (EP= 10 V), collision cell exit potential (CXP=10 V). The data 
were acquired with Analyst software, Version 1.5.   
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Table 4-1: LC-MS/MS parameters for API 4000 Qtrap system. 
Peptide 
Charge 
State 
Retention 
time (mins) 
MRM Transitions 
(Parent ion → Fragment ion) 
CE 
( Volts) 
GDSVVYGLR +2 4.2 m/z 483.9-508.6 24 
GDSVVYGLR +2 4.2 m/z 483.9-607.8 22 
#
GDSVVY +1 4.0 m/z 639.3-359.4 30 
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Figure 4-2: LC-MS/MS Instrumentation. A: Block diagram of the conventional flow LC-
MS/MS system. B: Block diagram of the MFLC-MS/MS system. 
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4.2.3.2 Microflow LC-MS/MS system  
The MFLC-MS/MS system consisted of a Waters NanoAcquity UPLC coupled to at Waters TQ-
S mass spectrometer fitted with a prototype ion key/MS™ separation device. The separation 
device consisted of a compact cartridge with an in-built capillary column having an internal 
diameter of 150 µm and packed with 1.7 µm particles. HPLC grade water with 0.1% formic acid 
and acetonitrile with 0.1% formic acid were used as mobile phase A1 and B1, respectively. The 
LC system was operated in the trap mode using a single pump system. A Symmetry C18 Guard 
Column, 300 µm x 50 mm from Waters (Milford, USA) was used as the trap column. Trapping 
was carried out for 2 minutes at a flow rate of 20 µL/min using 99.5% mobile phase A1. 
Analytical separation was performed on a Waters BEH 130 C18 iKey™ Separation Device  
(100 mm x 150 μm I.D., 1.7 μm). Gradient conditions were as follows: 0.0–0.5 min, isocratic 5% 
B1; 0.5 –3.0 min, linear from 5% to 20% B; 3.0 –5 min, linear from 20% to 30% B; 5.0 –7.0 
min, linear from 30% to 95% B; 7.0 –8.4 min, isocratic 95% B; 8.4 –8.5 min, linear from 95% to 
5%; 8.4 –8.5 min, isocratic 5% B. The total running time was 9 min and the injection volume 
was 20 µL in the full loop mode. Initial flow rate from 0.0 to 0.5 min was kept at 0.5 μL/min to 
avoid high back pressure during switch over from trapping to analysis mode. From 0.5 to 8.5 
minutes, the chromatographic separation was carried out at a flow rate of 2.5 μL/min. The flow 
rate was changed to 1.0 μL/min after 8.5 min. The cone voltage and collision energy were 
optimized for each compound using automatic tuning (Intellistart system) in the TQ-S. The 
parameters for each compound are listed in Table 4-2. The capillary voltage was 3.6 kV, the 
source temperature was 100 °C, the source offset was 60 V, and the collision gas was argon. 
Dwell times for all transitions were 0.044 s. The MFLC-MS/MS apparatus is diagrammatically 
illustrated in Figure 4-2. 
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Table 4-2: LC-MS/MS parameters for Xevo TQS System 
Peptide 
Charge 
State 
Retention 
time 
(mins) 
MRM Transitions 
Cone 
Voltage 
( V) 
Collision 
Energy 
(V) (Parent ion → 
Fragment ion) 
GDSVVYGLR 2 5.0 m/z 483.6-508.5 15 16 
GDSVVYGLR 2 5.0 m/z 483.6-607.5 15 16 
GDSVV*YGLR 2 5.0 m/z 486.0-508.5 19 14 
GDSVVYGLR* 2 5.0 m/z 488.6-518.4 19 14 
TYDGRGDSV*VYGLRSKSKKF 3 4.6 m/z 568.6-669.4 37 16 
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4.2.4 Method Development Studies 
4.2.4.1 Signature Peptide Selection  
In-silico digestion studies were carried out using Protein Prospector version 5.10.9 (UCSF Mass 
Spectrometry Facility California, USA). Trypsin was chosen as the proteolytic enzyme. 
Following the in- silico digest, the peptides were subjected to sequence homology analysis in the 
human plasma proteome using the Basic Local Alignment Search Tool (BLAST) software. 
4.2.4.2 Digestion Optimization 
A 50 µL aliquot of recombinant hOPN standard solution of 10 ng/mL was used for digestion 
studies. Digestion was carried out in 50 mM ammonium bicarbonate buffer using three different 
amounts of trypsin i.e. 5, 50 and 500 ng per sample. The samples were not reduced with 
dithiothreitol (DTT) and iodoacetamide since hOPN is devoid of cysteine di-sulfide bonds.  
Samples were withdrawn at various time intervals i.e. 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 10.5, 13, 20, 22, 
24 hours. The reaction was terminated by adding formic acid. The samples were stored at -20°C 
until analysis.  
4.2.4.3 Immunocapture method optimization 
4.2.4.3.1 Order of Addition  
Commercially available monoclonal antibodies ‘MAB 193P’ which were specific to hOPN, and 
having affinities for a site distant from the signature peptide i.e. 
‘31QLYNKYPDAVATWLNPDPSQKQNLLAP’ were used for immunoaffinity isolation. The 
biotinylated capture antibodies were immobilized on high binding capacity streptavidin coated 
96 microwell plates and used for immunocapture. Three different strategies were evaluated for 
the order of assembly of the immobilized antibody/immunocapture reaction. In Strategy I, 
immobilization of antibody was carried out prior to OPN immunocapture.  Strategy II involved 
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the formation of OPN-antibody complex prior to antibody immobilization. Strategy III allowed 
the antibody immobilization and immunocapture reaction to occur simultaneously. The strategy 
with the highest yields was used in the final method. Recombinant human osteopontin (rhOPN) 
was spiked in plasma to obtain a concentration of 50 ng/100 µL (not adjusted for baseline plasma 
OPN level). Healthy volunteer plasma was randomly chosen for this experiment. Unspiked 
plasma samples were processed as blanks to account for endogenous levels of OPN. JMP Pro 
(version 10.0.2) software was used for statistically comparing the results. The three strategies for 
immunocapture were as follows: 
A)  Strategy I (Immobilization – Immunocapture): In this biotinylated antibody (1 ug), 
diluted in a IC buffer, was  added to streptavidin coated plates and incubated for 4 hours 
at  room temperature on a rotary shaker. After 4 hours, the plates were washed three 
times with IC wash buffer and 100 µL of the sample was added and incubated for 4 or 20 
hours at on a rotary shaker. The plates were then washed and the immunocaptured protein 
was digested. 
B) Strategy II (Immunocapture – Immobilization):  An aliquot of 100 µL of the sample was 
incubated with the antibody in 1.5 mL Eppendorf
®
 Lobind centrifuge tubes for 4 or 20 
hours on a rotary shaker. After 20 hours, the samples were transferred to streptavidin 
coated plates and incubated for 4 hours at room temperature on a rotary shaker. The 
plates were then washed and the immunocaptured protein was digested. 
C) Strategy III (Immunocapture + Immobilization):  An aliquot of 100 µL of the sample 
along with antibody was added to streptavidin coated plates and incubated for 20 hours 
on a rotary shaker. After 20 hours, the plates were washed and the immunocaptured 
protein was digested. 
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4.2.4.3.2 Optimization of the amount of Antibody 
The use of streptavidin coated 96-well plates as the solid support restricted the sample volume to 
100 µL. On the conventional LC-MS/MS system, higher sample volumes were required to 
achieve lower detection limits, hence the method was modified to use streptavidin coated beads 
for immobilization. However, when the method was transferred to the MFLC-MS/MS system, 
the higher sensitivity allowed switching to the 96-well plate format. To evaluate the impact to 
varying the amount of antibody on the method, rhOPN was spiked in plasma having low baseline 
concentrations to achieve a final concentration of 600 ng/mL and analyzed as per the sample 
preparation procedure described under validation studies, with varying amounts of antibody. The 
antibody amounts used were 0.031, 0.063, 0.125, 0.250, 0.500, 1.000, 2.000 and 4.000 µg per 
well. Each level was analyzed in triplicate. The response was measured as the ratio of peak area 
of the signature peptide to that of the internal standard.  
4.2.5 Evaluation of internal standards 
4.2.5.1 Comparison of digestion profiles of hOPN and internal standards 
Tryptic digestion of the rhOPN along with the SIL peptide ‘GDSVVYGLR*and the extended 
SIL peptide ‘TYDGRGDSVV*YGLRSKSKKF’ was carried out for 0, 1, 2, 3, 4, 5, 7, 8, 10, 14 
and 25 hours.  
4.2.5.2 Evaluation of forced and inherent digestion variability of hOPN using SIL-IS and 
extended SIL-IS. 
Recombinant protein was added to 50mM ammonium bicarbonate buffer to obtain 3 different 
concentration levels i.e. 80, 200 and 500 ng. These standards were digested in replicate (n=8) 
along with the two internal standards for 2, 7 and 14 hours. Digestion variability was induced 
artificially by using different amounts of trypsin i.e. 100, 500 and 900 ng to attain 20%, 100% 
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and 180% trypsin activity, respectively. Analyte/IS peak are ratio was used as response. Average 
response was calculated from standards having 100% trypsin activity. Inherent variability was 
expressed as the percent difference in the response obtained from standards with 100% trypsin 
activity from the average response, whereas forced variability was measured as the percent 
difference of the response of standards with 20% and 180% trypsin activity from the average 
response. Brown-Forsythe test of unequal variance was used to compare the variance. As the 
analysis involved 18 comparisons, a level of significance of α=0.003, obtained after Bonferroni 
correction, was used. 
4.2.6 Method Validation Studies 
Validation was carried out using guidelines set forth in the May 2001 US FDA Guidance for 
Industry – Bioanalytical Method Validation  (2001, USFDA 2001). Due to the lack of an internal 
standard control during the immunoaffinity isolation step, a wider accuracy and precision 
acceptance criteria (20/25%) typically used for ligand-binding assays was be applied to this 
validation. Both internal standards, the SIL-IS peptide and the extended SIL-IS peptide, were 
added to all analysis. SIL-IS peptide was used as the primary internal standard to assess the 
validity of the method. The extended SIL-IS was used to evaluate its impact on the precision of 
the method. Two SRM transitions for the signature peptide were included in the final method but 
only the response from fragment ion m/z 508.5 was used for quantitative analysis as it was found 
to show less interference from co-eluting peptides. 
4.2.6.1 Preparation of standards and quality control samples 
The stock solution of rhOPN was prepared at 100 µg/mL in PBS and stored at -80°C as 50 µL 
aliquots in 0.5 mL Protein LoBind tubes (Eppendorf
®
). Calibration standards and quality control 
samples were prepared in surrogate matrix and plasma. Immuno-capture (IC) buffer was used as 
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a surrogate matrix. Previously screened human plasma samples having low endogenous OPN 
levels were pooled and used for preparation of plasma calibration standards and quality control 
samples.  The calibration standards were prepared by adding appropriate amounts of stock 
solution or subsequent calibration standards to the surrogate matrix or plasma. Nominal 
concentrations in surrogate matrix standards were 25.0, 52.7, 79.0, 118.5, 177.8, 266.7, 400.0, 
600.0 ng/mL of hOPN.  The same procedure was used for creation of quality control (QC) 
samples at three concentration levels, denoted as lower limit of quantification (LLOQ) QC, low 
quality control (LQC), medium quality control (MQC) and high quality control (HQC) having  
concentrations of 25.0, 101.0, 235.7, 550.0 ng/mL of hOPN, respectively. The nominal 
concentrations in plasma standards after adjusting for endogenous baseline concentrations were 
60.8, 88.6, 114.9, 154.4, 213.6, 302.5, 435.8, 635.7 ng/mL of hOPN.  The plasma quality control 
(QC) samples, denoted as plasma lower limit of quantification (pLLOQ) QC, plasma low quality 
control (pLQC), plasma medium quality control (pMQC) and plasma high quality control 
(pHQC), had  concentrations of 60.8, 101.0, 235.7 and 550.0 ng/mL respectively after adjusting 
for endogenous baseline concentrations. 
4.2.6.2 Sample Preparation 
Biotinylated anti-hOPN monoclonal antibodies (0.5 µg/well) were immobilized on high capacity 
streptavidin coated 96 well plates (Thermo scientific, USA). Samples were diluted 40 fold with 
IC buffer and 100 µL of the diluted sample was added to each well. Immunocapture was carried 
out at room temperature for 4 hours using a constant vortex of 450 rpm. After 4 hours, the plates 
were washed 3 times with immunocapture wash buffer. Digestion was carried out by adding 100 
µL of digestion solution to each well and incubating the plates at 37°C in a water bath for 14 
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hours. Digestion was terminated by adding 2 µL formic acid to each well. The digested samples 
were transferred a Protein LoBind 96 well plate and analyzed using LC-MS/MS.   
4.2.6.3 Linearity and LLOQ 
Calibration standards were extracted in duplicate and analyzed in 3 independent runs.  
Calibration curves were fitted using linear 1/x
2
 weighted regression of the ratio of the peak area 
response of the analyte and that of the internal standard versus concentration.  
4.2.6.4 Accuracy and Precision 
Accuracy and precision were determined from quality controls samples spiked in surrogate 
matrix and in three independent runs processed on two different days.  Intra-day assay precision 
and accuracy were determined from QC samples of two validation runs processed on the same 
day. Inter-day assay precision and accuracy were determined by analyzing three different 
validation runs processed on two separate days. Primary evaluation was carried out using SIL-IS. 
Extended SIL-IS was used only for comparison. 
4.2.6.5 Dilution Integrity 
An "over-the-curve" quality control sample, with hOPN concentration of 1035.5 ng/mL, was 
prepared and used as a plasma dilution quality control sample (pDI QC). The samples were 
analyzed with the sample preparation procedure after a two and four fold dilution in replicate. A 
criterion of ±20% of the nominal concentration was used to assess the dilution integrity. 
4.2.6.6 Stability Studies 
Stability studies were assessed using QC samples spiked in surrogate and pooled plasma at two 
levels LQC and HQC.  For post-preparative stability, the quality control samples were processed 
and maintained at 2-8°C for 9 days prior to analysis. Short term storage stability at -80 °C was 
assessed after 18 days.  Only plasma quality control samples were used to assess freeze-thaw 
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stability after subjecting the samples to four freeze thaw cycles.  To assess bench top stability, 
the QC samples were thawed and left on the bench at room temperature for 24 hours. All 
stability samples were analyzed against a freshly spiked calibration standard curve. The stability 
studies were deemed acceptable if the coefficient of variation of the replicate determinations did 
not exceed 20.0% and the accuracy of the mean value is within ±20.0% of the theoretical value 
for that pool for both the QC levels. 
4.2.6.7 Selectivity and Matrix Effect 
Dilution of plasma samples in the surrogate matrix was used to avoid matrix inferences. Slopes 
of the calibrations curve obtained from standards prepared in surrogate matrix were compared 
with a calibration curve obtained from standards prepared in plasma. JMP Pro (version 10.0.2) 
software was used. Slopes of the calibration curves and confidence intervals were obtained using 
linear regression. Slopes were considered parallel if there was an overlap of the confidence 
intervals. Parallel slopes would indicate no matrix differences between the two matrices.  
Four human plasma samples from healthy volunteers and four human plasma samples from 
breast cancer patients were analyzed in triplicate, both with and without fortification of hOPN at 
the LLOQ-level. Additionally, these samples fortified with only internal standards were also 
analyzed. Selectivity requirements were that any peak area co-eluting in the unfortified plasma 
samples at the retention time of the internal standards must be less than 5% of the average peak 
area of the individual internal standards. Spike recovery was assessed after subtraction of the 
basal concentrations and the percent deviation from nominal (%DFN) was evaluated using an 
acceptance criterion of ±25 %. 
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4.2.7 Evaluation of internal standards ability to account for digestion variability in the 
final method 
Digestion variability was induced using different amounts of trypsin during digestion. 
Calibration standards prepared in IC buffer were processed as per the sample preparation 
procedure. Quality control samples at two levels (LQC, HQC) were prepared in IC buffer and 
processed as per the sample preparation procedure with varying amount of trypsin. The trypsin 
amounts used were 100 ng, 400 ng, 500 ng, 600 ng and 900 ng representing 20, 80, 100, 120 and 
180 percent variability in trypsin activity, respectively. Six replicate samples were analyzed at 
each trypsin level. The OPN concentrations obtained with 100% trypsin activity were used to 
calculate average concentrations at each level. Plots of percent deviation from average 
concentrations (100% trypsin activity) versus percent trypsin activity were used to assess the 
impact of trypsin variability on precision. The variance was compared using Brown-Forsythe 
test. 
4.2.8 Evaluation of plasma OPN levels in breast cancer patient and healthy individuals. 
Samples from breast cancer patients (n=10) were purchased from Biochemed services and 
healthy individual plasma samples (n=10) were randomly chosen from the in-house inventory at 
Pharmaceutical Product Development, LLC (PPD), Richmond, USA. These samples were 
analyzed with the validated method.  
4.3 RESULTS AND DISCUSSION 
4.3.1 Method Development 
4.3.1.1 Signature Peptide Selection 
A tryptic peptide ‘160GDSVVYGLR’ was chosen as the signature peptide after the in-silico 
investigations. This amino acid sequence was unique for hOPN from a BLAST search of the 
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Homo sapiens genome using UniProtKB/Swiss-Prot. Since this peptide (GDSVVYGLR) 
contains functional domains such as the integrin binding site of hOPN (RGDSVVYGLR) and the 
sites for proteolytic cleavage by MMPs and CPB-2, this tryptic peptide is a biologically relevant 
signature peptide of hOPN.  
 
Figure 4-3: Schematic of the method procedure. 
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Additionally, this peptide did not show any post-translational phosphorylation, thus avoided an 
additional dephosphorylation step during sample processing. The schematic representation of 
method procedure is show in Figure 4-3. 
4.3.1.2 Conventional Flow LC-MS/MS Method 
Synthetically manufactured signature peptide (GDSVVYGLR) was used for development of LC-
MS/MS conditions. The mass spectra showed that a peak corresponding to the +2 charge state of 
the peptide was the most intense and was used as the precursor ion. The selected precursor ion 
was fragmented and the two most intense fragment ions (y4 and y5) were chosen for the method 
(see Table 4-1). The signal responses obtained from both SRMs of the signature peptide were 
summed in the final quantitation method to achieve lower detection limits. 
Column trapping to allow online sample enrichment prior to separation on the analytical column 
was used. After initial digestion studies, the gradient conditions of the method were further 
modified by varying the gradient steepness to resolve a digestion by-product (GDSVVY) peak 
from the signature peptide peak. Evaluation of hOPN calibration standards, prepared in digestion 
buffer, showed that the calibration curve was linear over the range of 100 – 1000 pg/mL with a 
mean correlation coefficient of 0.9972. A weighting factor of 1/x was used. No internal standard 
was used during analysis on this system.  
4.3.1.3 Digestion Optimization 
Initial digestion studies showed that the time profile plot of the signature peptide concentration 
was biphasic indicating that the signature peptide obtained on digestion of hOPN was unstable 
(Figure 4-4). Such trends have been observed in other studies involving tryptic digestions 
(Agger, et al. 2010, Brownridge, et al. 2011a, Proc, et al. 2010, van den Broek, et al. 2013b). To 
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investigate the decrease in peptide concentration over time, the synthetic signature peptide was 
incubated with and without trypsin. A decrease in peptide concentration over time was seen 
which was not seen with controls that did not contain trypsin. The results indicated that the 
signature peptide was being degraded in the presence of trypsin. To determine possible 
degradation products, the signature peptide was incubated with trypsin and the digests were 
analyzed using LC-MS/MS in the precursor ion scan mode. The probable masses of cleaved 
products of the signature peptide were obtained using Protein Prospector software and the 
chromatograms were scanned for the presence of these cleaved products. The chromatograms 
showed a peak with mass of 693.4 Da corresponding to the cleaved product ‘GDSVVY’. The 
authenticity of the peak was verified by conducting a product ion scan. As the cleavage took 
place on the carboxy terminal end of tyrosine, it indicated an enzymatic activity similar to 
chymotryptic digestion. Trypsin is known to undergo autolysis and may show a chymotrypsin-
like activity(Tryspin gold mass spectrometry grade technical bulletin Part # TB309 Revised 03/13). It 
was speculated that cleavage of the signature peptide was a result of trypsin autolytic activity. A 
SRM method was developed to measure the cleaved product (see Table 4-1). In addition, the 
chromatographic gradient was modified to resolve the peaks of the signature peptide and cleaved 
product. 
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Figure 4-4: Digestion profile of hOPN with varying amount of tryspin. 
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Digestion studies with different amount of trypsin showed that the highest signature peptide 
yields were obtained between 5-10 hours using 500 ng of trypsin per sample (see Figure 4-4). 
The digestion efficiency was found to be around 35-40 %. 
4.3.1.4 Immunocapture method optimization  
4.3.1.4.1 Order of addition 
The signature peptide yields using the Strategy I, II and II are given in Figure 4-5. Adjusted 
signature peptide concentrations were obtained after subtracting the average blank plasma 
concentrations.  
From Figure 4-5, it can be seen that the highest signature peptide yield was obtained when the 
samples were processed using Strategy I i.e. when immobilization of the antibody on a solid 
support is carried out prior to the immunocapture reaction. A probable reason could be that the 
immobilization of the “naked” capture antibody is more efficient compared to that of the 
preformed antigen-antibody complex due to steric hindrance. Also, no significant difference in 
signature peptide yield was seen between immunocapture incubation carried out for 4 hours and 
20 hours for Strategy I. Hence, Strategy I with 4 hour immunocapture incubation was used for 
further studies. In the final method, the immobilization time was changed from 4 hours to 2 
hours. 
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Figure 4-5: Immunocapture optimization studies (Order of addition). 
 
 
 
 
 
 
 
 
 
 
 
  
91 
 
 
4.3.1.4.2 Optimization of the amount of Antibody 
The result of antibody amount optimization studies is given in Figure 4-6. A ‘hook-effect’ was 
seen due to excess coating of monoclonal antibody on the streptavidin coated plates. An 
assumption is that overcrowding of the immobilized antibodies results in steric hindrance, thus, 
negatively affecting the immuno-complex formation. When more than 0.5 µg of antibody was 
used per well, a decline in response was seen followed by response saturation with an increasing 
amount of antibody. The final method used 0.5 µg of antibody per well, since the highest 
response was obtained at this concentration. 
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Figure 4-6: Immunocapture optimization studies (Antibody amount). 
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4.3.1.5 Evaluation of internal standards 
A peptide ‘GDSVVYGLR*’ having the same sequence as the signature peptide and containing 
an arginine labeled with 
13
C6 and 
15
N4 was used as the SIL-IS peptide. Another peptide 
‘TYDGRGDSVV*YGLRSKSKKF’ having the same sequence as the signature peptide along 
with additional amino acid chains flanking both terminal ends and containing a valine labeled 
with 
13
C5 and 
15
N was used as the extended SIL-IS peptide. The amino acid chains flanking the 
terminals were chosen from the hOPN sequence.  As hypothesized, comparison of the tryptic 
digestion time profiles showed that the extended SIL-IS peptide better mimicked hOPN digestion 
than the SIL-IS peptide (See Figure 4-7).  
The extended SIL peptide and hOPN digestion profiles can be divided into three phases i.e. the 
‘formation phase’, the ‘transition phase’ and the ‘degradation phase’. The formation phase 
represent the incubation period between 0-5 hours which is dominant in the formation of 
signature peptide or SIL signature peptide from the digestion of hOPN and extended SIL peptide, 
respectively. The transition phase represent the incubation period between 5-10 hours where 
signature peptide formation and degradation processes occur at similar rates. The degradation 
phase represents the incubation period beyond 10 hours in which degradation of the signature 
peptide is the most dominant phenomenon. In the case of the SIL peptide, only degradation is 
occurring.   
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Figure 4-7: Comparison of digestion profiles of hOPN and the two internal standards. 
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Variability during trypsin digestion can occur due number of reasons including interfering 
substances in  complex biological matrix, lot-to-lot variation in trypsin stock solution and 
inadequate removal of surfactants or chaotropic agents from prior sample processing steps. This 
variability can be tracked by adding an appropriate internal standard (Bronsema, et al. 2013, 
Brownridge, et al. 2011a, Proc, et al. 2010, van den Broek, et al. 2013a). In order to assess the 
ability of the two internal standards to account for digestion variability, digestion was carried out 
in replicate (n=8) at three different OPN concentration levels and three different amounts of 
trypsin (100ng, 500 ng and 900 ng). Digestion was stopped at three time intervals (2, 7 and 14 
hours) representing the ‘formation phase’, ‘the transition phase’ and ‘the degradation phase’. The 
average response of samples digested with 500 ng trypsin was used to calculate the variability 
which was expressed as the percent difference from the average. The term ‘inherent digestion 
variability’ was used to represent variability at 100 % trypsin activity i.e. using 500 ng of trypsin 
per sample, while ‘forced digestion variability’ was used to represent variability seen at 20 and 
180 % trypsin activity.  
The inherent and forced digestion variability, across the three phases with the two internal 
standards, is shown in Figure 4-8 and 4-9, respectively. In these figures, the QC levels 01, 02, 03 
represent the 80, 200 and 500 ng/ml of OPN concentrations, respectively. The whiskers of the 
box plots seen in these figures represent range and is a measure of the variability seen in the 
response. Brown Forsythe test of unequal variance was used to compare the standard deviations 
of the percent deviation from average in the individual groups. The statistical results of this test 
are available in supporting information (Table 4-3). The standard deviation of the percent 
deviation from average can be used as measure of precision i.e. lesser standard deviation values 
would represent higher precision and vice-versa. 
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From Figure 4-8, one can observe that the inherent digestion variability decreased with increase 
in digestion time when SIL-IS was used. For results analyzed with extended SIL-IS, the 
precision was least at 7 hours and highest at 14 hours. The high variability at 7 hours could be 
attributed to the transition phase wherein there is simultaneous occurrence of signature peptide 
formation and degradation.  Highest precision was seen at 14 hours primarily because at this time 
interval only a single degradation process is dominant. It was seen that there was no significant 
difference between the responses obtained using the two internal standards (see Table 4-3).  Thus 
we can conclude that the use of either internal standard does not have an impact on the inherent 
variability. Also, except for QC_02 samples at 2 hours, all the box plot in Figure 4-8 had their 
box plot whiskers within ± 20%. This indicates good precision using both internal standards. 
From Figure 4-9, it can be observed that the forced digestion variability decreased with 
increasing digestion time when SIL-IS was used. However, when extended SIL-IS was used the 
variability at 7 hours was higher than 2 and 14 hours. The least variability was seen at 14 hours.   
This trend is similar to the inherent trend observed for inherent digestion variability. At each 
time interval, the variability decreased with increasing OPN concentration. This was more 
prominent for the responses analyzed using SIL-IS.  Also, the variability in the responses 
analyzed using SIL-IS was significantly higher (see Table 4-3) in comparison to the response 
analyzed using extended SIL-IS, except for QC_03 samples at 7 and 14 hours. It can be seen that 
the data points analyzed using SIL-IS are more focused near the interquartile range instead of the 
median.  
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Figure 4-8: Evaluation of internal standards ability to account for digestion variability 
(inherent). 
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Figure 4-9: Evaluation of internal standards ability to account for digestion variability 
(forced). 
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In contrast, the responses analyzed using extended SIL-IS are more focused around the median 
indicating that the trypsin activity variation had a smaller impact on the final response.  Also, it 
can be seen that there is a significant difference in the precision at all-time points except QC-03 
samples at 7 and 14 hours (see Table 4-3).  Response obtained using extended SIL-IS showed 
higher precision in comparison to SIL-IS. Thus we can conclude that the extended SIL peptide 
would be a better internal standard when a digestion variability between samples is expected. 
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Table 4-3: Results of digestion variability studies using different internals standards 
Variability 
 Type 
Time  
(Hours) 
QC 
Level  
 Extended SIL-IS SIL-IS  Brown-Forsythe Test   
(Std Dev) (Std Dev) (F Ratio) (p-value) 
Inherent 2 1 10.68 14.67 0.0040 0.9502 
Inherent 2 2 16.29 19.62 0.0314 0.8618 
Inherent 2 3 8.57 6.51 0.9208 0.3536 
Inherent 7 1 12.31 6.34 2.4068 0.1431 
Inherent 7 2 13.22 13.51 0.4010 0.5376 
Inherent 7 3 19.86 10.52 0.4795 0.5 
Inherent 14 1 4.65 7.12 0.8653 0.368 
Inherent 14 2 5.81 5.22 0.0018 0.9665 
Inherent 14 3 5.10 7.77 0.5267 0.48 
Forced 2 1 21.91 61.61 87.3208 <.0001* 
Forced 2 2 22.65 65.71 119.4768 <.0001* 
Forced 2 3 14.81 56.98 324.2888 <.0001* 
Forced 7 1 17.30 42.16 120.9018 <.0001* 
Forced 7 2 27.30 40.62 12.0396 0.0016* 
Forced 7 3 28.96 35.46 4.5444 0.0413 
Forced 14 1 14.16 34.50 65.2119 <.0001* 
Forced 14 2 11.22 26.49 46.4727 <.0001* 
Forced 14 3 15.06 25.24 3.6225 0.0666 
*   p-value < Level of significance α =0.003  
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4.3.2 Method Transfer 
The initial method used conventional flow HPLC coupled to a Sciex API 4000 Qtrap mass 
spectrometer. This method had a lower limit of quantification of 100 pg/ml for the signature 
peptide prepared in digestion buffer.  The detectability limit of the signature peptide and the low 
overall sample processing efficiency of the method (17%) restricted the method range to a lower 
limit of 5 ng/ml of hOPN using 500 µL of sample. Biomarker investigations usually have limited 
sample availability. This was the primary reason for method transfer to the MFLC-MS/MS 
system. In addition, we wanted to evaluate the microflow LC system for regulated quantification 
of large molecules. The microflow LC system had a 1226 times higher signal-to-noise ratio as 
compared to the conventional flow LC system. This allowed us to lower the sample volumes to 
20 uL while achieving similar detection limits. The conventional flow method used streptavidin 
coated magnetic beads for immunocapture which were necessary due to the high sample volume. 
The low sample volume of the new method allowed the immunocapture to be performed on more 
convenient high binding capacity streptavidin coated plates. In addition, the lower detection 
limits of the microflow LC system allowed for further sample dilution to avoid matrix 
interferences. The use of low flow rates also resulted in a 100-fold reduction in solvent 
consumption. 
4.3.3 Method Validation Studies 
A prime concern during method development was establishment of the method validation range. 
As discussed earlier, there is ambiguity in reported absolute concentrations of hOPN in 
biologically samples, primarily due to the differences between individual ELISA kits.  For this 
reason, eights lots of healthy individual plasma lots were randomly chosen from the in-house 
inventory at PPD and screened to establish baseline plasma OPN levels. An average 
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concentration of 49±17 ng/mL (mean + SD) was obtained from the screened samples. A 4-10 
fold increase in OPN levels has been observed in diseased populations relative to healthy 
individuals from previous studies involving immunoassays(Rodrigues, et al. 2007). Hence, a 
concentration range of 25-600 ng/mL, which includes mean baseline concentration and a 10-fold 
increase in baseline concentrations, was chosen for the validation studies. 
4.3.3.1 Selectivity and Matrix Effect 
A common challenge in biomarker analysis is to select an appropriate matrix in which to prepare 
the standard curve. Ideally, this should be free of target analytes and identical to the sample 
matrix. To avoid matrix effects between individual lots, each sample was diluted 40-fold prior to 
immunocapture. This high dilution allowed use of the IC buffer as a surrogate matrix.  
From Figure 4-10, it can be seen that the calibrations curves prepared using plasma standards and 
surrogate matrix standards are parallel. The plasma concentrations were not adjusted to account 
for baseline levels. The slope of the surrogate matrix i.e. IC buffer curve was 0.00073 (95% 
Lower confidence interval = 0.0067 and 95% Upper confidence interval = 0.00078) while the 
slope of the plasma curve was 0.00074 (95% Lower confidence interval = 0.0066 and 95% 
Upper confidence interval = 0.00081). The overall of 95% confidence interval of both slopes 
indicates that the slopes are not significantly different. Hence, we can conclude that any matrix 
difference that may exist would not preclude selective quantification provided the samples are 
diluted 40-fold prior to immunocapture. 
No interfering peak was present at the retention time of an internal standard.   Spike recovery 
ranged from -13.1 to 19.2% in all the fortified samples after adjusting for the baseline levels. 
Representative chromatograms of the blank samples prepared in buffer and plasma are given in 
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Figure 4-11 and 4-12, respectively. Representative chromatograms of LLOQ standard prepared 
in buffer and plasma are given in Figure 4-13 and 4-14, respectively. 
 
Figure 4-10 : Parallelism experiment to demonstrate the suitability of the surrogate matrix i.e. 
IC buffer. 
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Figure 4-11: Representative chromatogram of blank (IC buffer) with SIL-IS. 
 
 
 
 
  
105 
 
 
Figure 4-12: Representative chromatogram of blank (IC buffer) with extended SIL-IS. 
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Figure 4-13: Representative chromatogram of LLOQ standard (IC buffer). 
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Figure 4-14: Representative chromatogram of LLOQ QC (plasma). 
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4.3.3.2 Linearity  
The standard curves demonstrated a linear response over the concentration range of 25-600 
ng/mL. The calibration curves yielded a mean (n=3) correlation coefficient of 0.9967. The 
percent deviation from nominal (%DFN) for the mean back-calculated values of the calibration 
standards were between -2.16% and 3.69%. Precision of the calibration standards measured as 
the percent relative standard deviation for the mean back-calculated values ranged from 2.98% to 
9.59%. 
4.3.3.3 Accuracy and Precision 
The limit of quantification (LLOQ) was established at 25 ng/mL and demonstrated a precision of 
10.7 % and 5.93 % in surrogate matrix and in plasma, respectively. The LLOQ demonstrated 
accuracy of -12.0 % and -1.21 % in surrogate matrix and in plasma, respectively. Intra-assay 
results of accuracy and precision for quality control samples using SIL-IS and extended SIL-IS 
are shown in Table 4-4 and 4-5. Inter-assay results of accuracy and precision for quality control 
samples using SIL-IS and extended SIL-IS are shown in Table 4-6 and 4-7. One LQC sample 
was excluded from statistically analysis citing sample processing error as demonstrated by low 
internal standard peak response.  Intra-assay and inter-assay precision with both internal 
standards was within 15%. No substantial advantage was seen in accuracy or precision with the 
use of extended peptide. Dilution integrity was established by analyzing ‘over-the-curve’ QC 
after a 2-fold and 4–fold dilution. The back calculated concentrations after analyzing DI QC 
samples post 2-fold and 4-fold dilutions yielded an accuracy of -11.83% and -7.60%, 
respectively and a precision of 6.97% and 5.04%, respectively. 
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Table 4-4: Intra-day accuracy and precision (SIL-IS) 
Matrix 
IC Buffer Plasma 
LQC MQC HQC LQC MQC HQC 
Nominal concentration 
(ng/ml) 
101.0 236.0 550.0 137.0 271.0 584.0 
Mean calculated  
concentration (ng/ml) 
99.3 230.0 568.7 127.8 253.8 540.3 
Standard deviation 7.52 8.02 38.28 10.25 22.27 25.65 
Percent coefficient of 
variation 
7.57 3.49 6.73 8.02 8.77 4.75 
Percent deviation from 
nominal concentration  
-1.67 -2.54 3.39 -6.70 -6.33 -7.49 
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Table 4-5: Intra-day accuracy and precision (extended SIL-IS) 
Matrix 
IC Buffer Plasma 
LQC MQC HQC LQC MQC HQC 
Nominal concentration 
(ng/ml) 
101.0 236.0 550.0 137.0 271.0 584.0 
Mean calculated  
concentration (ng/ml) 
99.7 222.3 569.3 130.8 249.9 560.8 
Standard deviation 9.03 8.43 35.90 10.88 16.16 25.22 
Percent coefficient of 
variation 
9.06 3.79 6.31 8.32 6.47 4.50 
Percent deviation from 
nominal concentration 
-1.29 -5.83 3.52 -4.51 -7.78 -3.97 
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Table 4-6: Inter-day accuracy and precision (SIL-IS) 
Matrix 
IC Buffer Plasma 
LQC MQC HQC LQC MQC HQC 
Nominal concentration 
(ng/ml) 
101.0 236.0 550.0 137.0 271.0 584.0 
Mean calculated  
concentration (ng/ml) 
101.0 235.0 574.0 123.0 254.0 524.0 
Standard deviation 6.78 12.8 33.9 22 23.2 42.9 
Percent coefficient of 
variation 
6.75 5.45 5.9 17.9 9.13 8.19 
Percent deviation from 
nominal concentration 
-0.47 -0.31 4.43 -10.00 -6.28 -10.30 
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Table 4-7: Inter-day accuracy and precision (extended SIL-IS). 
Matrix 
IC Buffer Plasma 
LQC MQC HQC LQC MQC HQC 
Nominal concentration 
(ng/ml) 
101.0 236.0 550.0 137.0 271.0 584.0 
Mean calculated  
concentration (ng/ml) 
103.0 234.0 580.0 130.2 254.0 542.0 
Standard deviation 8.98 21.2 38 10.50 21.4 41.4 
Percent coefficient of 
variation 
8.72 9.06 6.56 8.06 8.43 7.65 
Percent deviation from 
nominal concentration 
1.92 -0.57 5.43 -4.94 -6.38 -7.25 
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4.3.3.4 Stability Studies 
The stock solution was stored at -80°C after reconstitution in phosphate buffered saline and it 
was stated to be stable for 3 months in those storage conditions as per supplier instructions. The 
plasma QC samples were found to be stable after 4-freeze thaw cycles. Short term stability was 
assessed for 18 days at -80°C and was found to be within specifications both matrices i.e. IC 
buffer and plasma. Samples thawed on the bench were found to be stable for 24 hours both 
matrices. Extracted samples from both matrices were found to be stable when stored at stored at 
2-8°C for 9 days. The stability studies results are given in Table 4-8. 
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Table 4-8: Results of Stability studies. 
Study Matrix Level N % DFN %CV 
Freeze thaw Stability 
 (4 cycles) 
Plasma 
LQC 6 19.08 4.13 
HQC 6 9.45 4.12 
Short Term Storage 
Stability (-80 °C)              
(18 days) 
IC Buffer 
LQC 6 15.78 3.18 
HQC 6 18.08 5.07 
Plasma 
LQC 6 17.34 3.01 
HQC 6 6.62 3.42 
Thawed Matrix Stability 
(24 Hours) 
IC Buffer 
LQC 6 16.00 3.60 
HQC 6 10.53 4.56 
Plasma 
LQC 6 14.02 4.34 
HQC 6 9.21 2.13 
Extracted Sample Stability 
(2-8 °C)            (9 Days) 
IC Buffer 
LQC 6 -0.49 3.60 
HQC 6 5.84 2.55 
Plasma 
LQC 5 -2.38 2.54 
HQC 6 -9.78 6.09 
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4.3.3.5 Evaluation of internal standards ability to account for digestion variability in the 
final method 
Ideally an internal standard's ability to account for variability is measured in controlled settings. 
As seen earlier precision and accuracy studies showed that there was no significant difference in 
precision or accuracy when either internal standard peptide was used. However, from initial 
experiments, we had seen that the extended SIL-IS peptide should be a better internal standard to 
account for variability in trypsin activity. The impact of trypsin variability on precision was 
assessed from the slopes of plots of percent deviation from the average assayed concentration (at 
100% trypsin activity) versus percent trypsin activity. A lower value for the slope would indicate 
that there is better precision and that the trypsin variability is lessened by the presence of the 
internal standard.  
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Figure 4-15 : Plots of the percent deviation from average concentrations (100% trypsin 
activity) versus percent trypsin activity. 
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 From Figure 4-15, it can be seen that use of the SIL peptide as an internal standard resulted in 
slopes of 0.418 and 0.567, obtained for LQC and HQC s, respectively. Alternatively, when the 
extended SIL peptide was used as the internal standard, plots were obtained with slopes of 0.031 
and 0.136 for LQC and HQC s, respectively. This suggests that during analysis of unknown 
samples, if a particular sample has diminished or enhanced trypsin activity, the impact of this on 
results would be less when using an extended SIL peptide as an internal standard. 
4.3.4 Evaluation of plasma OPN levels in breast cancer patient and healthy individuals. 
An average OPN concentration of 55.4±15.3 ng/mL was determined in the plasma samples of 
healthy volunteers (see Figure 4-16). Plasma OPN concentrations in breast cancer patients were 
elevated and ranged from 85-637 ng/mL. In particular, 30% of the samples (n=10) showed more 
than 9-fold increase over the mean plasma concentrations in healthy volunteers. As OPN plays 
an important role in cancer progression (Rodrigues, et al. 2007), a probable speculation is that 
these plasma samples were from patients with advanced disease. Since these plasma samples 
were purchased from a commercial source, this could not be confirmed due to the lack of 
availability of additional disease information on these patients. 
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Figure 4-16: Comparison of plasma OPN levels in healthy individuals and breast cancer 
patients. 
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4.4 CONCLUSION 
We developed and validated a method for quantification of human osteopontin from plasma 
using a capillary microflow LC-MS/MS system. The use of microflow LC-MS/MS platform 
resulted in 1226 times increase in signal-to-noise ratio, which in turn, allowed the use of lower 
sample volumes and reduced solvent consumption. This method demonstrated applicability of 
Waters iKey/MS™ separation device for regulated analysis of proteins. 
The quantification was carried out by using a biologically relevant signature peptide 
GDSVVYGLR that was obtained after tryptic digestion of immunocaptured OPN. Validation 
was carried out using IC buffer as a surrogate matrix. A 40-fold dilution, prior to 
immunocapture, enabled avoidance of matrix effects. The method was accurate, precise and 
demonstrated good linearity over the range of 25-600 ng/mL. Stability studies demonstrated 
good bench-top, post preparative, freeze thaw and storage stability. 
The selected signature peptide showed an additional chymotrypsin-like cleavage during digestion 
resulting in degradation of the peptide. In order to ensure that any variability that could arise 
from the two processes of peptide formation and degradation occurring simultaneously, internal 
standardization prior to digestion was incorporated in the method. A SIL peptide and an 
extended SIL peptide were evaluated as internal standards. Validation studies showed that under 
controlled conditions and long digestion time there was no significant difference in precision 
when either of the internal standards as used. However, when trypsin activity was forcibly 
varied, the extended SIL peptide was found to give better precision. This difference was more 
pronounced at when digestion was carried out at shorter time intervals. 
The applicability of the method for measuring plasma OPN levels was demonstrated by 
analyzing samples obtained from breast cancer patients and healthy individuals. Breast cancer 
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patient samples demonstrated elevated plasma OPN concentrations. The method range covers 
both healthy as well as diseased population plasma OPN concentrations. Human osteopontin can 
undergoes post-translational proteolytic cleavage which can interfere in its quantification in 
ligand binding assays. Considering its use as a biomarker, this method ensures that the captured 
hOPN is biologically active by using a biologically relevant signature peptide. Thus, this method 
is proposed as an alternative to ELISA and for measuring plasma OPN concentrations during 
oncological screening and monitoring.  
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CHAPTER 5 
 
 
5 DEVELOPMENT OF AN IN-VITRO CELL BASED SYSTEM FOR EVALUATION 
OF TOBACCO PRODUCTS FOR CARDIOVASCULAR RISK BY MEASURING 
THE SECRETED OSTEOPONTIN LEVELS IN TOBACCO EXTRACT EXPOSED 
ENDOTHELIAL CELLS 
 
 
5.1 INTRODUCTION 
Mass spectrometry based methods show great promise as an alternative to immunoassays for 
quantification of protein biomarkers (Makawita, et al. 2010, Ramanathan, et al. 2011, Rauh 
2012). Mass spectrometry provides a universal platform for selective analysis of biomarker 
proteins. In particular, a mass spectrometer has the ability to differentiate between a biomarker 
protein and its post-transnationally modified form (Makawita, et al. 2010, Wang, et al. 2009). In 
this chapter, our objective was to develop a mass spectrometry based method to simultaneously 
measure secreted human osteopontin and its matrix metalloproteinase-3 (MMP-3) cleaved N-
terminal fragment and to use this method to develop an in-vitro cell-based system to evaluate 
tobacco products for cardiovascular risk. 
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 The tobacco plant has been smoked, chewed, or inhaled for many centuries (Willis, et al. 2012). 
Smoked tobacco, mainly cigarettes, has been the predominant form of tobacco use. In the US, 
smokeless tobacco (ST) has gained tremendous popularity in last few decades (Delnevo, et al. 
2014). This popularity can be attributed to a number of factors, including an unsupported 
perception of safety; apparent health advantages of ST use over smoked tobacco; increased 
smoke-free laws across the country; the ease of use in a concealed manner; and a substitute 
product for smoking cessation (Piano, et al. 2010). 
Many forms of ST products exist worldwide such as snus, snuff, chewing tobacco, gutka, pan 
and mishri. In the United States, the predominant forms of ST products are chewing tobacco and 
snuff (Delnevo, et al. 2014, Willis, et al. 2012).Chewing tobacco is available as loose leaves, 
plugs (bricks), or twists of rope and is placed between the cheek and lower lip, typically toward 
the back of the mouth (Willis, et al. 2012). It is either chewed or held in place. Snuff is finely cut 
or powdered tobacco. It is packaged moist or dry; most American snuff is moist (also referred to 
as snus). It is available loose, in dissolvable lozenges or strips, or in small pouches similar to tea 
bags. A pinch or pouch of moist snuff is placed between the cheek and gums or behind the upper 
or lower lip (Willis, et al. 2012).  
Cigarette smoking has been associated with a number of harmful effects including an increased 
risk for cancer, cardiovascular diseases, chronic obstructive pulmonary disease and asthma . 
Cigarette smoking is known to promote atherosclerosis mainly through pathological processes 
such as endothelial dysfunction, inflammation and thrombosis (Unverdorben, et al. 2009, 
Winkelmann, et al. 2009). Presently, there is not a full understanding of the mechanisms 
underlying the susceptibility of tobacco users to cardiovascular disease which is due in part to a 
lack of knowledge about all the constituents present in tobacco products (Bishop, et al. 2012). 
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Also, there is a lack of standardized in vitro testing systems for tobacco products (Johnson, et al. 
2009). 
A recent study showed that non-cytotoxic concentrations of cigarette smoke particulate matter 
increased osteopontin levels in cultured human endothelial cells (Bishop, et al. 2012). This effect 
was reduced in the presence of ascorbate, thus these researchers associated smoking particulate 
matter exposure to increased oxidative stress. In addition, a particulate matter concentration 
dependent rise in matrix MMP-3 was observed in these experiments. As osteopontin is known to 
be cleaved by MMP-3 to form a bioactive fragment (Agnihotri, et al. 2001), thus, a potential role 
of the osteopontin fragment is implicated. Also, the study showed that serum osteopontin levels 
were significantly lowered as compared to those measured prior to smoking cessation in smokers 
who quit smoking for 5 days, thus showing an agreement with the conclusion of the cell 
exposure studies (Bishop, et al. 2012). 
Currently, there is no standard ELISA for measuring OPN, which has been the major limitation 
for clinical development of OPN as a biomarker in cancer. In fact, studies have shown that OPN 
blood concentrations measured with different ELISAs gave different absolute values ranging 
from nanogram per milliliter to milligram per milliliter (Anborgh, et al. 2009, Blum, et al. 2012, 
Plumer, et al. 2008). In addition, western blot is the only way to measure MMP-3 cleaved 
osteopontin fragments. Western blot methods are semi-quantitative and have issues with 
antibody cross-reactivity. Hence, there is a need for development of a quantitative method that 
can simultaneously measure osteopontin and osteopontin fragments (thrombin and/or MMP 
cleaved products) from a biological matrix. One of the objectives of this chapter was to develop 
a method to simultaneously measure secreted human osteopontin and its MMP-3 cleaved N-
terminal fragment from supernatants of endothelial cells.   
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Considering osteopontin as a biomarker of endothelial dysfunction (Scatena, et al. 2007, 
Shimada, et al. 2005, Waller, et al. 2010), we hypothesized that a cell based system as described 
by Bishop et al, could be used to assess the cardiovascular risk. A specific objective of this 
chapter, was to develop a cell based in vitro system for evaluation of tobacco products for 
cardiovascular risk toxicity studies related to tobacco regulation. An immortalized human 
umbilical vascular endothelial cell line i.e. EA.hy926, was used to avoid variability arising due to 
use of primary cells. The study objective was to measure and correlate levels of secreted 
osteopontin and the MMP-3 cleaved N-terminal osteopontin fragment from the cell based system 
upon tobacco product exposure. A significantly high level of osteopontin in comparison to non-
exposed controls would indicate endothelial dysfunction.  
In our preliminary investigations, digestion studies of human osteopontin showed an interfering 
peak in the chromatogram of the MMP-3 cleaved N-terminal fragment of human osteopontin. 
Thus, we concluded the LC-MS/MS method, using signature peptides obtained from the 
biologically relevant zone i.e. ‘RGDSVVYGLR’, would not be able to distinguish between full 
human osteopontin and MMP-3 cleaved N-terminal fragment of human osteopontin. 
Additionally, EA.hy926 cells were exposed to cigarette smoke extract and its supernatant was 
evaluated for secreted osteopontin levels. It was observed that the secreted osteopontin 
concentration in supernatant of cell culture studies were below detection limits. Since the 
preliminary results did not indicate that this research objective could be addressed with the 
proposed system, this study was terminated. 
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5.2 MATERIALS AND METHODS 
5.2.1 Reference Materials 
Recombinant hOPN was purchased from R&D Systems (Minneapolis, MN, USA). Signature 
peptides having the amino acid sequence ‘GDSVVYGLR’ and ‘GDSVVYG’ for hOPN and the 
MMP-3 cleaved N-terminal hOPN fragment, respectively, were synthesized by Elim 
Biopharmaceuticals (Hayward, CA, USA).  A stable isotope labeled (SIL) peptide having the 
sequence ‘GDSVVYGLR*’, containing an arginine residue labeled with 13C and 15N4 was 
synthesized by Thermo Scientific (Rockford, IL, USA) and used as the SIL-IS. The labeled 
arginine residue resulted in a mass shift of 10 amu from the mass of the OPN-SP. In this chapter, 
we will refer to the full OPN signature peptide (GDSVVYGLR) and to the MMP-3 cleaved N-
terminal hOPN fragment signature peptide (GDSVVYG) as ‘OPN-SP’ and ‘OPN-SP-1’, 
respectively. 
5.2.2 Reagents and Chemicals 
Cigarette smoke concentrate was purchased from Murthy Pharmaceuticals (Lexington, KY, 
USA). Dulbecco's Modified Eagle's Medium (DMEM), fetal bovine serum (FBS), trypsin EDTA 
solution (1x), Dulbecco's phosphate buffered saline (D-PBS) and EA.hy926 cells were purchased 
from American Type Culture Collection (ATCC). Protease inhibitor cocktail tablets were 
obtained from Roche (Indianapolis, IN, USA). HPLC grade water with 0.1% formic acid and 
acetonitrile with 0.1% formic acid were purchased from Honeywell Burdick & Jackson 
(Muskegon, MI, USA). High grade water was obtained using a Milli-Q integral water 
purification system (Billerica, MA, USA). Formic acid, methanol, Trizma hydrochloride (1M), 
bovine serum albumin and tween 20 were purchased from Sigma-Aldrich (Saint Louis, MO, 
USA). Glacial acetic acid was obtained from Macron Fine Chemicals (Center Valley, PA, USA). 
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Sodium chloride solution (5 M) and EDTA solution (0.5M) were obtained from Ambion (Foster 
City CA, USA). Trypsin Gold was obtained from Promega (Madison, WI, USA). Biotinylated 
antibodies specific to hOPN (MAB193P) were obtained as a gift from Maine Biotechnology 
Services (Portland, Maine, USA).  Immuno-capture (IC) buffer and IC wash buffer were 
prepared in-house and were comprised of 0.1/ 5.0/ 3.0 /0.2 /91.7 /0.1(v//v/v/v/w) Tween 20/ 
Trizma HCl (1M)/ NaCl (5M)/EDTA (0.5M)/water/ bovine serum albumin and 
5.0/3.0/0.2/91.8/0.1 (v/v/v/v) Trizma HCl (1M)/ NaCl (5M)/ EDTA (0.5M)/ water, respectively. 
Digestion solution, containing of 500 ng/100 µL of trypsin gold,  0.05 pg/100 µL of SIL-IS 
peptide and 0.68 pg/100 µL of extended SIL-IS peptide in 50 mM ammonium bicarbonate 
buffer, was freshly prepared prior to digestion for the validation studies.  
5.2.3 LC-MS/MS method  
The LC-MS/MS system consisted of a Waters NanoAcquity UPLC system coupled to at Waters 
TQ-S mass spectrometer fitted with an ion key/MS™ separation device. The separation device 
consisted of a compact cartridge with an in-built capillary column having an internal diameter of 
150 µm and packed with 1.7 µm particles. HPLC grade water with 0.1% formic acid and 
acetonitrile with 0.1% formic acid were used as mobile phase A1 and B1, respectively. The LC 
system was operated in the trap mode using a single pump system. A Symmetry C18 Guard 
Column, 300 µm x 50 mm from Waters (Milford, USA) was used as the trap column. Trapping 
was carried out for 2 minutes at a flow rate of 20 µL/min using 99.5% mobile phase A1. 
Analytical separation was performed on a Waters BEH 130 C18 iKey™ Separation Device 
(100 mm x 150 μm I.D., 1.7 μm). Gradient conditions were as follows: 0.0–0.5 min, isocratic 5% 
B1; 0.5 –3.0 min, linear from 5% to 20% B; 3.0 –5 min, linear from 20% to 30% B; 5.0 –7.0 
min, linear from 30% to 95% B; 7.0 –8.4 min, isocratic 95% B; 8.4 –8.5 min, linear from 95% to 
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5%; 8.4 –8.5 min, isocratic 5% B. The total running time was 9 min and the injection volume 
was 20 µL in the full loop mode. The initial flow rate from 0.0 to 0.5 min was kept at 0.5 μL/min 
to avoid high back pressure during switch over from trapping to analysis mode. From 0.5 to 8.5 
minutes, the chromatographic separation was carried out at a flow rate of 2.5 μL/min. The flow 
rate was changed to 1.0 μL/min after 8.5 min. The cone voltage and collision energy were 
optimized for each compound using automatic tuning (Intellistart system) in the TQ-S. The 
parameters for each compound are listed in Table5-1. The capillary voltage was 3.6 kV, the 
source temperature was 100 °C, the source offset was 60 V, and the collision gas was argon. 
Dwell times for all transitions were 0.044s.  
5.2.4  Sample Preparation 
Biotinylated anti-hOPN monoclonal antibodies (1 mg/ well) were immobilized on high capacity 
streptavidin coated 96 well plates (Thermo scientific, USA). Samples were diluted 4-fold with IC 
buffer and 100 µL of the diluted sample were added to each well. Immunocapture was carried 
out at room temperature for 4 hours using a constant vortex of 450 rpm. After 4 hours, the plates 
were washed 3 times with immunocapture wash buffer. Digestion was carried out by adding 100 
µL of digestion solution to each well and incubating the plates at 37°C in a water bath for 14 
hours. Digestion was terminated by adding 2 µL formic acid to each well. The digested samples 
were transferred a Protein LoBind 96 well plate and analyzed using LC-MS/MS.   
5.2.5 Digestion Studies 
Mass spectrometric parameters for OPN-SP1 were determined using a Waters Intellistart system. 
The retention time for this peptide was determined using the chromatographic method developed 
in chapter 4. Human osteopontin stock solution was spiked in 50 mM ammonium bicarbonate 
solution to obtain OPN standard solution having concentrations of  39.1, 78.1, 156.3, 312.5.625, 
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1250 and 2500 ng/mL.    A 500 uL aliquot of the OPN standard solution was incubated with 200 
ng of MMP-3 in a 2 ml Lobind Eppendorf centrifuge tube for 3 hours at 37 °C. The reaction is 
terminated by heating at 95 °C for 15 minutes. These samples were then digested with 500 ng of 
trypsin at for 14 hours at 37 °C along with controls that were not treated with MMP-3. The 
digestion was terminated by adding 10 uL formic acid. The samples were then transferred to an 
autosampler plate and analysed by LC-MS/MS. 
5.2.6 Cigarette Smoke Extract Exposure studies 
5.2.6.1 Method modifications 
Human osteopontin standard solutions (100 and 500 ng/mL) were prepared by spiking 
recombinant hOPN in IC buffer or DMEM media, with and without complete protease inhibitor, 
from cell culture flasks used for sub-culturing the EA.hy926 cells. The standards were analyzed 
for the amount of human osteopontin using GDSVVYGLR as the signature peptide using the 
LC-MS/MS method. A modified method that was developed in Chapter 4 was used.  The 
modification included a 4-fold dilution of the samples prior to immunocapture instead of   a 40-
fold dilution. The method was evaluated for capture differences between the DMEM media (with 
and without complete protease inhibitor) and IC buffer. 
5.2.6.2 Exposure studies 
Immortalized human umbilical vein endothelial cells (EA.hy926 cells) were cultured in DMEM 
and fetal bovine serum (10%). The plates were incubated in at 37°C in a 5% CO2 humidified 
atmosphere. Cells were seeded at 1×10
5
 cells/well to allow approximately 80% confluence at the 
time of media harvest, after all exposure studies. Cigarette smoke extract (CSE) containing 
40mg/ml particulate matter and 1.7 mg nicotine was purchased from a commercial vendor and 
diluted with DMEM + 10% FBS.  
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Cells were treated for 24hr either with cigarette smoke extract or nicotine or with 0.5% DMSO 
as a diluent control. In all exposure studies, the concentrations used of particulate matter was 20, 
40, 60 and 100 µg/ml, and concentration used of nicotine was 0.85, 1.7, 2.6 and 4.25 µg/ml in 
the exposure studies. After 24 hours, the media from the plates was aliquoted into a 1.5 ml 
Lobind Eppendorf centrifuge tube containing complete EDTA-free protease inhibitor cocktail. 
The samples were processed as per sample preparation procedure and analyzed using LC-
MS/MS along with hOPN standards (8-500 ng/ml). 
5.3 RESULTS AND DISCUSSION 
Mass spectrometric parameters obtained during tuning of the OPN-SP1 are given in Table 5-1. 
The b5 fragment ion (m/z 458.31) had the highest intensity and its mass transition was included 
in method developed in Chapter 4. Chromatographic evaluation of the synthetic signature 
peptide using the LC-MS/MS method developed in Chapter 4 showed a peak at the retention 
time of 4.6 mins.  
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Table 5-1: Mass spectrometric Parameters of GDSVVYG 
Compound 
 
Parent m/z 
Cone 
Voltage 
Daughters 
Collision 
Energy 
GDSVVYG 
1 696.67 50 458.31 18 
2 696.67 50 72.04 50 
3 696.67 50 136.03 50 
4 696.67 50 341.22 28 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
131 
 
5.3.1 Digestion Studies 
OPN digestion study results with MMP-3 and trypsin are given Table 5-2. It can be seen that 
OPN digestion with MMP-3 and trypsin resulted in the formation of GDSVVY.  A linear 
increase in the peak area of the GDSVVYG peptide was seen in the digestion carried out with 
MMP3 and Trypsin. Digest fragments increased with an increasing amount of OPN as seen 
Figure 5-1. However, when OPN was digested only with trypsin, small amount of GDSVVYG 
peptide were obtained as see in Table 5-2. This unexpected GDSVVYG peptide formation 
during trypsin digestion would interfere in the simultaneous quantitative estimation of full hOPN 
and MMP-3 cleaved N-terminal fragment of hOPN.  
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Table 5-2: Evaluation of the GDSVVYG fragment from OPN digest samples 
OPN Concentration (ng/ml) 
Average OPN-SP2 (GDSVVYG)                     Peak 
Area (cps) 
Trypsin Digestion 
(n=2) 
 MMP-3 + Trypsin Digestion 
(n=3) 
39.1 850 2858 
78.1 2299 3465 
156.3 1335 2506 
312.5 1312 5345 
625.0 1087 8133 
1250.0 2918 9494 
2500.0 3092 16051 
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Figure 5-1: GDSVVYG formation upon digestion of hOPN with MMP-3 and trypsin 
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5.3.2 Cigarette smoke extract exposure studies 
The method developed in chapter 4 was modified for the immunocapture step to accommodate 
changes in the sample matrix i.e. DMEM cell media and to increase the amount 
immunocaptured. The method developed in chapter 4 was modified for the immunocapture step 
wherein a 4-fold dilution of the sample was carried out prior to immunocapture instead of a 40-
fold dilution. This modification in the method enabled higher amount of immunocaptured 
protein. From Figure 5-2, it can be observed that there was no significant difference in the 
immunocaptured hOPN amount between the hOPN standards prepared in IC buffer and DMEM 
buffer. This modified procedure was used for analyzing samples obtained in the cigarette extract 
exposure studies in EA.hy926 cells. 
The study conducted by Bishop et al, used HUVECs to demonstrate secretion of hOPN upon 
exposure to cigarette smoke particulate matter.  HUVECs are primary cells and have an average 
life span of 10 serial passages and can be kept in culture for maximum of 5 months (BouÃ¯s, et 
al. 2001). We wanted a more rugged immortalized cell based system that could be routinely used 
in different laboratories ensuring good reproducibility. In order to improve reproducibility and 
life span in culture, we chose an immortalized HUVEC cell line i.e. EA.hy926 cells for this 
study.  EA.hy926 are obtained from a fusion of HUVEC and lung carcinoma cell A549 and it is 
the most widely used immortalized HUVECs (BouÃ¯s, et al. 2001). 
In the study conducted by Bishop et al, HUVECs were exposed for 24 hours to cigarette smoke 
particulate matter and this resulted in a dose dependent increase in the concentration of secreted 
osteopontin in the media (Bishop, et al. 2012). In our study, the cigarette smoke extract was 
obtained from a commercial source. The extract was certified to contain 40 mg/ml of particulate 
matter and 1.7 mg/ml of nicotine. The cigarette smoke extract was obtained by smoking 
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University of Kentucky's 3R4F Standard Research Cigarettes on an FTC Smoke Machine.   
Nicotine exposure in human-derived osteoblast-like cells, aortic vascular smooth muscle cells 
and human pancreatic ductal adenocarcinoma cells have shown an increase in osteopontin levels 
(Chipitsyna, et al. 2009, Walker, et al. 2001, Wang, et al. 2012b). We wanted to investigate 
whether or not nicotine alone had an impact on the osteopontin levels in our study. Hence, in our 
investigation, cells were treated with nicotine controls at concentrations similar to those seen in 
the cigarette smoke extract. 
The media from the exposure study was evaluated using the modified immunocapture method 
described earlier along with calibration standards which were prepared by spiking recombinant 
hOPN in IC buffer. In the study conducted by Bishop et Al., the study showed an average 
concentration of 14 ng/ml in the DMSO controls.  Expecting similar hOPN concentrations, 
hOPN calibration standards having a concentration range of 8-500 ng/ml were used during the 
analysis of the exposure study samples.  The osteopontin levels were found to be below detection 
limits in all the samples in the exposure study including the DMSO controls. The study was 
repeated again with the same particulate matter concentrations for 48 hours. However, the 
osteopontin levels in all samples were still found to be below the detection limit. A possible 
reason could be that EA.hy926 cells secreted osteopontin at concentrations much lower than 
those seen in the HUVEC exposure studies.  Variability in the detected hOPN concentrations 
between different commercially available immunoassay kits has been reported. Thus, another 
reason could be that the absolute hOPN levels in the HUVEC study may be inaccurate i.e. 
overestimated.  
As the exposure studies did not yield measurable osteopontin levels in the cell media, it would be 
very challenging to use this cell line for development of the in-vitro cell based system for routine 
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screening of tobacco products. Since the preliminary results did not indicate that this research 
objective could be addressed with the proposed system, this study was terminated. 
 
 
Figure 5-2: Evaluation of matrix on hOPN immunocapture 
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5.4 CONCLUSION 
In 2009, the US Congress passed the Family Smoking Prevention and Tobacco Control Act 
mandating regulation of the tobacco industry by the Food and Drug Administration (FDA) 
through the FDA Center for Tobacco Products (CTP) (Prevention 2009). Since then there has 
been an increase in the need for in-vitro tools for regulating tobacco products (Hecht 2012, 
Leischow, et al. 2012). Based on the findings of Bishop et al., we proposed an in-vitro cell based 
system to evaluate tobacco products for cardiovascular risk. The primary objective of this system 
was to simultaneously measure secreted osteopontin and the MMP-3 cleaved N-terminal 
osteopontin fragment using LC-MS/MS from media of cells exposed to tobacco product extracts. 
However, our preliminary studies indicated that our proposed LC-MS/MS strategy would not be 
able to simultaneously measure full hOPN and its MMP-3 cleaved fragment due to an 
unexpected interference seen at the retention time of signature peptide for the MMP-3 cleaved 
fragment of hOPN.  In addition, our initial tobacco extract exposure studies in an immortalized 
endothelial cell line did not yield detectable osteopontin levels. Since the preliminary results did 
not indicate that this research objective could be addressed with the proposed system, this study 
was terminated. 
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 CHAPTER 6 
 
 
6 AN EXTENDED STABLE ISOTOPE LABELED SIGNATURE PEPTIDE 
INTERNAL STANDARD FOR TRACKING IMMUNOCAPTURE OF HUMAN 
OSTEOPONTIN FOR LC-MS/MS QUANTIFICATION 
 
 
Drawn from manuscript submitted to Biomedical Chromatography., August 2014 
 
 
6.1 INTRODUCTION 
Internal standardization is an important aspect of the method development process for mass 
spectrometry based quantification of proteins. Various internal standardization strategies for 
mass spectrometry based protein quantification have been proposed previously and reported in 
several review articles (Bronsema, et al. 2012, Brun, et al. 2007, Pailleux, et al. 2012, van den 
Broek, et al. 2013a). Ideally internal standards should compensate for all variations encountered 
during sample processing as well as instrumental response fluctuations.  Sample processing steps 
usually involve a protein purification step and an enzymatic digestion step. The most commonly 
used internal standard for protein quantification is a stable isotope labeled (SIL) form of the 
signature peptide, commonly referred to as the SIL-IS peptide. A SIL-IS peptide contains amino 
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acids labeled with the stable isotopes of 
13
C or 
15
N thus it is physiochemically identical to the 
signature peptide but can be easily differentiated on the mass analyzer due to the mass difference 
imparted by the presence of the isotope. The major advantage of using a SIL-peptide is that these 
can be synthetized at relatively low cost.  A SIL-peptide IS is usually added before enzymatic 
digestion and can efficiently compensate for extraction recovery, peptide instability and LC-
MS/MS variability. However, they do not account for proteolytic digestion variability or any 
variation in the protein purification processes (Brun, et al. 2009, Li, et al. 2012).  
 A cost effective internal standardization variability in digestion efficiency is achieved by using 
extended SIL-IS peptides. An extended SIL-peptide, i.e. a SIL-IS peptide having cleavable 
groups flanking either side of side of a SIL-peptide,  is added prior to digestion  and these have 
shown to compensate for variability in digestion efficiency in addition to extraction recovery, 
peptide instability and LC-MS/MS instrumental  variability. (Barnidge, et al. 2004, Neubert, et 
al. 2013, Ocana, et al. 2010).  
In order to compensate for variability arising during protein purification, a SIL-IS protein may be 
required. SIL-proteins can be obtained by incorporating stable isotope labeled amino acids into 
the target protein (Ong 2002, Picard, et al. 2012). This can be achieved using metabolic labeling 
by incubating cells in a medium containing stable isotope labeled amino acids popularly known 
as Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) (Ong 2002). Alternatively, 
SIL-proteins can also be made by in vitro protein synthesis in a cell free system or can be 
chemically synthesized if it a small protein (Jian, et al. 2013).  SIL-protein standards may be 
ideal internal standards for protein quantifications as they can compensate for immunoaffinity 
isolation variability, enzymatic digestion variability, extraction recovery, peptide instability and 
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LC-MS/MS variability. However, a major drawback of SIL proteins is a lack of commercial 
availability and high cost. 
Human osteopontin (hOPN) is a secreted biomarker protein which is present in various 
biological fluids including blood, milk and urine (Lund, et al. 2009). It is implicated in a variety 
of disease states, including cardiovascular disorders, cancer, and several chronic inflammatory 
diseases (Lund, et al. 2009, Rodrigues, et al. 2007, Waller, et al. 2010). In our previous work, we 
developed and validated an immunoaffinity coupled liquid chromatography tandem mass 
spectrometry (LC-MS/MS) method to quantify human osteopontin from plasma using a 
biologically relevant signature peptide GDSVVYGLR (Faria, et al.). We also demonstrated the 
advantages of using an extended stable isotope labeled (SIL) signature peptide as an internal 
standard (IS) to compensate for digestion variability. In that method however, the internal 
standardization did not compensate for immunocapture variability as internal standard was added 
post immunocapture.  
We hypothesized that an extended SIL-IS peptide could be used to compensate for 
immunocapture variability during protein quantification provided that immunocapture is carried 
out with an antibody that binds to a common epitope present on both the protein and SIL-IS 
peptide. This hypothesis is based on the assumption that any change in immunocapture 
efficiency should impact analyte protein and IS peptide binding proportionally.  In a proof of 
concept investigation, we demonstrated the ability of an extended SIL-IS peptide to compensate 
for immunocapture variability using a hOPN specific antibody (MAB222P) that has an epitope 
in the signature peptide region (DSVVYG) of the protein. A schematic of the quantification 
strategy is shown in Figure 6-1.  
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Figure 6-1: Strategy for human osteopontin qunatification using an antibody selective for the 
signature peptide 
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6.2 EXPERIMENTAL 
6.2.1 Reagents and Chemicals 
Recombinant hOPN (rhOPN) was purchased from R&D Systems (Minneapolis, MN, USA). The 
OPN signature peptide (OPN-SP), with an amino acid sequence ‘GDSVVYGLR’, was 
synthesized by Elim Biopharmaceuticals (Hayward, CA, USA). An extended SIL peptide 
(TYDGRGDSVV*YGLRSKSKKF) and a SIL peptide (GDSVVYGLR*), obtained from 
Thermo Scientific (Rockford, IL, USA), were used as the IS peptide I and IS peptide II, 
respectively. The IS peptide I upon cleavage by trypsin yielded GDSVV*YGLR. The labeled 
amino acids V* and R* had additional mass of 6 and 10 Da, respectively. HPLC grade water 
with 0.1% formic acid and acetonitrile with 0.1% formic acid were purchased from Honeywell 
Burdick & Jackson (Muskegon, MI, USA). High grade water was obtained using a Milli-Q 
integral water purification system (Billerica, MA, USA). Bovine serum albumin, Dulbecco’s 
phosphate buffered saline, formic acid, methanol, Trizma hydrochloride (1M) and tween 20 were 
purchased from Sigma-Aldrich (Saint Louis, MO, USA). Glacial acetic acid was obtained from 
Macron Fine Chemicals (Center Valley, PA, USA). Sodium chloride solution (5M) and EDTA 
solution (0.5M) were obtained from Ambion (Foster City CA, USA). Trypsin Gold was obtained 
from Promega (Madison, WI, USA). Biotinylated antibodies to hOPN (MAB222P) were 
obtained as a gift from Maine Biotechnology Services (Portland, Maine, USA). The product 
information for MAB222P antibodies state that they have affinity towards  the ‘DSVVYG’ 
amino acid sequence of hOPN.   Immuno-capture (IC) buffer was prepared in-house and was 
comprised of 0.1/5.0/3.0/0.2/91.7/0.1 (v//v/v/v/w) Tween 20/ Trizma HCl (1M)/ NaCl 
(5M)/EDTA (0.5M)/water/ bovine serum albumin. IC wash buffer was prepared in-house and 
was comprised of 5.0/3.0/0.2/91.8/0.1 (v/v/v/v) Trizma HCl (1M)/ NaCl (5M)/ EDTA (0.5M)/ 
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water, respectively. Digestion solution, containing of 500 ng/100 µL of trypsin gold, 0.05 pg/100 
µL of SIL-IS peptide II in 50 mM ammonium bicarbonate buffer, was freshly prepared prior to 
digestion for validation studies.  
6.2.2 Instrumentation  
The MFLC-MS/MS system consisted of a Waters NanoAcquity UPLC coupled to at Waters TQ-
S mass spectrometer fitted with a prototype ion key/MS™ separation device. The separation 
device consisted of a compact cartridge with an in-built capillary column having an internal 
diameter of 150 µm and packed with 1.7 µm particles. HPLC grade water with 0.1% formic acid 
and acetonitrile with 0.1% formic acid were used as mobile phase A1 and B1, respectively. The 
LC system was operated in the trap mode using a single pump system. A Symmetry C18 Guard 
Column, 300 µm x 50 mm from Waters (Milford, USA) was used as the trap column. Trapping 
was carried out for 2 minutes at a flow rate of 20 µL/min using 99.5% mobile phase A1. 
Analytical separation was performed on a Waters BEH 130 C18 iKey™ Separation Device 
(100 mm x 150 μm I.D., 1.7 μm). Gradient conditions were as follows: 0.0–0.5 min, isocratic 5% 
B1; 0.5 –3.0 min, linear from 5% to 20% B; 3.0 –5 min, linear from 20% to 30% B; 5.0 –7.0 
min, linear from 30% to 95% B; 7.0 –8.4 min, isocratic 95% B; 8.4 –8.5 min, linear from 95% to 
5%; 8.4 –8.5 min, isocratic 5% B. The total running time was 9 min and the injection volume 
was 20 µL in the full loop mode. Initial flow rate from 0.0 to 0.5 min was kept at 0.5 μL/min to 
avoid high back pressure during switch over from trapping to analysis mode. From 0.5 to 8.5 
minutes, the chromatographic separation was carried out at a flow rate of 2.5 μL/min. The flow 
rate was changed to 1.0 μL/min after 8.5 min. The cone voltage and collision energy were 
optimized for each compound using automatic tuning (Intellistart system) in the TQ-S.  
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Table 6-1 : Sumamry of LC-MS/MS Paramters 
Peptide Sequence 
Retention 
time 
(mins) 
Selected Reaction 
Monitioring (SRM) 
Transitions 
Cone 
Voltage 
(V) 
Collision 
Energy 
(V) (Parent ion → 
Fragment ion) 
 
GDSVVYGLR 
5.0 m/z 483.6-508.5 15 16 
GDSVV*YGLR 5.0 m/z 486.0-508.5 19 14 
GDSVVYGLR* 5.0 m/z 488.6-518.4 19 14 
TYDGRGDSV*VYGLRSKSKKF 4.6 m/z 568.6-669.4 37 16 
 *Stable Isotope labeled amino acid 
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The parameters for each compound are listed in Table 6-1. The capillary voltage was 3.6 kV, the 
source temperature was 100 °C, the source offset was 60 V, and the collision gas was argon. 
Dwell times for all transitions were 0.044 s.  
Table 6-1.   Sumamry of LC-MS/MS Paramters 
6.2.3 Preparation of Standard Solution  
Recombinant hOPN standard was reconstituted in dulbecco’s phosphate buffered saline to 
prepare a stock solution of 100 µg/ml. Osteopontin calibration standard solutions of varying 
concentrations ranging from 25-1000 ng/ml were obtained by spiking hOPN stock solution in IC 
buffer.  
6.2.4 Sample Preparation Procedure 
Commercially available monoclonal antibodies ‘MAB 222P’, which were specific to hOPN and 
which had affinities for a specific site on the signature peptide (‘DSVVYG’), were used for 
immunoaffinity isolation. Biotinylated anti-hOPN monoclonal antibodies were immobilized on 
high capacity streptavidin coated 96 well plates (Thermo scientific, USA). 100 µL of the 
osteopontin calibration standard solution was added to each well along with a 50 µL aliqout of IS 
peptide I solution. Immunocapture was carried out at room temperature for 4 hours using a 
constant vortex of 450 rpm. After 12 hours, the plates were washed 3 times with immunocapture 
wash buffer. Digestion was carried out by adding 100 µL of digestion solution containing IS 
peptide II to each well and incubating the plates at 37°C in a water bath for 14 hours. Digestion 
was terminated by adding 2 µL formic acid to each well. The digested samples were transferred 
to a Protein LoBind 96 well plate and analyzed using LC-MS/MS.  
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6.2.5 Immunocapture variability evaluation 
Biotinylated anti-hOPN monoclonal antibodies (750 ng per well) were immobilized on high 
capacity streptavidin coated 96 well plates and used for analysis varying hOPN concentration 
(25-600 ng/ml) to evaluate linearity of the method.  
Immunocapture variability was forcibly induced by varying the antibody amount i.e. 150, 240, 
400, 650, 1050, 1710, 2770 and 4500 ng per well, thus resulting in varying immunocapture 
efficiency. A hOPN standard solution of 250 ng/ml was used for all samples in this study. The 
samples were processed as per sample preparation procedure and analysed using LC-MS/MS. 
The results were expressed as the percent difference from the average response ratio (analyte/IS 
peptide I and analyte/IS peptide II) obtained in samples analyzed with the nominal samples.  
6.3 RESULTS AND DISCUSSION 
Each sample was processed with internal standard addition prior and post immunocapture using 
two different IS peptide. Our earlier investigations in chapter 4 showed that under controlled 
digestion conditions, the precision is the same when either internal standard is used. This 
investigation was conducted under controlled digestion conditions, so we assume that there was 
no bias in the digestion variability when either IS peptide is used. 
The immunocapture efficiency of the antibody used in this study was 300 fold less than the 
antibody used in our previous method. Due to this low absolute recovery, this method was used 
only as a proof-of-concept study and was not developed into a fully validated method. 
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Figure 6-2: Linearity using modified method 
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The method developed in Chapter 4 was modified, wherein the immunocapture was carried out 
with a different antibody whose epitope site’ DSVVYG” was within the selected signature 
peptide (GDSVVYGLR). The modified method yielded a linear response with varying 
concentration of hOPN as seen from Figure 6-2. This indicates that the system is not saturated 
for this hOPN range (25-600 ng/ml) using wells coated with 750 ng of antibody. 
A logarithmic increase in analyte peak area was seen with increasing amount of antibody per 
well (see Figure 6-3). A deviation from linearity was observed at 1050 ng in the antibody amount 
versus analyte area curve for that OPN concentration, indicating saturation of the immunocapture 
capacity. Hence, samples analyzed with 1050 ng antibody per well were used as nominal 
samples. 
A logarithmic increase in IS peptide I (IS added prior to immunocapture) peak area was seen 
with an increasing amount of antibody per well (see Figure 6-4). On the other hand, a flat 
relationship was seen in the IS peptide I (IS added after immunocapture) peak area was seen with 
an increasing amount of antibody per well (see Figure 6-5).   
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Figure 6-3: Plot of Analyte peak area versusamount of immunocapture antibody. 
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Figure 6-4: Internal standard peptide I (added prior to immunocapture) peak area with a 
varying amount of immunocapture antibody. 
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Figure 6-5: Internal standard peptide II (added after immunocapture) peak area with a 
varying amount of immunocapture antibody  
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Figure 6-6: Evaluation of internal standard peptide addition in the immunocapture variability 
study 
 
 
 
 
 
 
 
 
 
 
 
  
153 
 
The comparison of impact of IS addition was before and after immunocapture was done by 
evaluating trend of the percent difference from the average response ratio (analyte/IS peptide I 
and analyte/IS peptide II) obtained in samples analyzed with the nominal samples.  From Figure 
6-6, it can be observed that the addition of an extended SIL-peptide IS before immunocapture 
compensated for immunocapture. This is shown as the flat trend (variability ranging from -
37.5% to 20.3%), as compared to the logarithmically increasing trend (variability ranging from -
80.9 % to 77.0 %) when IS was added post immunocapture.  
6.4 CONCLUSIONS 
This study demonstrates that an extended SIL-IS peptide can be used as an internal standard to 
compensate for immunocapture variability during quantification of hOPN by LC-MS/MS. 
Extended peptides may be considered as potential internal standards to account for sample 
processing variability (immunocapture and digestion) during protein quantification using 
immunoaffinity coupled LC-MS/MS. Use of extended SIL-peptides provides a cost effective 
internal standardization strategy as an alternate to the use of SIL-proteins. This internal 
standardization strategy could be used for quantification of low abundance biomarker proteins 
which require immunocapture purification, but do not have commercially available SIL-IS 
proteins. 
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CHAPTER 7 
 
 
7 OVERALL CONCLUSIONS 
 
 
 
Biomarker quantification plays an important role in clinical disease diagnosis, patient 
stratification, therapy selection and therapeutic monitoring (Fleming, et al. 2012, Goodsaid, et al. 
2007, Pletcher, et al. 2011). In addition, biomarkers are increasingly being used by the 
pharmaceutical industry as surrogate end point markers during drug development to have shorter 
clinical trials (Kola, et al. 2004, Lee, et al. 2009). Proteins are the functional biomolecules in 
biologically processes. Proteins found in biological fluids such as blood, urine, saliva and milk 
are preferred as biomarker molecules, primarily due to the ease of sampling (Dhingra, et al. 
2005, Rogers, et al. 2008). Protein biomarker application can involve measurement of the 
amount of protein or of the protein activity. Currently, protein biomarker quantification is 
dominated by immunoassays. Over the last few decades, immunoassays platforms have 
improved from the use of radioimmunoassay to enzyme linked immunosorbent assays (ELISA) 
(Hoofnagle, et al. 2009). Immunoassays provided a high sensitivity, high throughput and cost 
effectiveness platform to quantify biomarkers. However, immunoassays suffer from selectivity 
issues leading to method inaccuracies. Method inaccuracy arising from lack of selectivity can 
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lead to biased results, in turn affecting clinical decisions (Hoofnagle, et al. 2009). This led us and 
others to evaluate alternative methods for quantification of biomarker protein molecules.  This 
dissertation focused on developing and validating mass spectrometry based methods for 
quantification of protein biomarkers.  
Liquid chromatography coupled to mass spectrometry has been the small molecule gold standard 
of quantitative analysis for quantification of small molecules for many years now. Over the last 
decade, mass spectrometry is increasingly being evaluated as an alternative to immunoassays for 
protein biomarker applications (Makawita, et al. 2010, Ramanathan, et al. 2011, Rauh 2012). In 
the first chapter, strategies for quantitative analysis of protein biomarker molecules using liquid 
chromatography tandem mass spectrometry were discussed.  Currently, the most widely used 
protein quantification strategy using LC-MS/MS involves the formation of unique peptides upon 
enzymatic digestion of the analyte protein (Berna, et al. 2009, Keshishian, et al. 2009, Makawita, 
et al. 2010, Rauh 2012, Wang, et al. 2009). These unique peptides, also known as signature 
peptides, are then analyzed as surrogate analytes using LC-MS/MS. Method development begins 
with in-silico digestion studies of the analyte protein, to identify potential signature peptides and 
their mass spectrometric transitions. Enzymatic digestions are then carried out preferably using 
recombinant analyte protein and the digests are screened for the presence of the signature 
peptides identified during in-silico studies. In the final optimization studies, the signature peptide 
that is most selective and has the highest signal intensity is chosen and used as the surrogate 
analyte for the protein. 
If the biomarker proteins are quantified from complex biological matrices, it is essential that 
there is a purification step to isolate the analyte protein or the signature peptide from unwanted 
matrix components (Berna, et al. 2009, Keshishian, et al. 2009, Makawita, et al. 2010, Rauh 
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2012, Wang, et al. 2009). Biomarker protein concentrations and their physicochemical properties 
are main considerations while choosing an appropriate purification strategy. An immuno-based 
purification is usually required if the biomarker protein is found in low nanogram levels. 
Sometimes a ‘double clean-up’ involving a protein purification step followed by a peptide 
purification step is used to achieve cleaner samples and lower detection limits. (Ahn, et al. 2009, 
Kushnir, et al. 2013, Neubert, et al. 2013). 
Internal standard (IS) selection is an essential method development step for mass spectrometry 
based quantitative analysis (Bronsema, et al. 2012, Brun, et al. 2007, Pailleux, et al. 2012, van 
den Broek, et al. 2013a). Though stable isotope labeled SIL-proteins are considered ideal internal 
standards during protein quantification by LC-MS/MS, SIL-peptides are used for internal 
standardization as they are more readily available and have lower cost. However, SIL-peptides 
lack the ability to compensate for variability arising from sample processing steps such as protein 
purification and enzymatic digestion (Bronsema, et al. 2012, Brun, et al. 2007, Pailleux, et al. 
2012, van den Broek, et al. 2013a). Extended SIL-peptides, i.e. SIL-peptides having additional 
amino acid residues flanking on either side, can be used as alternatives to SIL-peptides to 
account for digestion variability (Bronsema, et al. 2012, Brun, et al. 2007, Pailleux, et al. 2012, 
van den Broek, et al. 2013a). In chapter 4, we have demonstrated the ability of an extended SIL-
IS peptide to account for digestion variability. In addition, we have demonstrated that an 
extended SIL-IS peptide can compensate for immunocapture variability when the epitope lies 
within the region of the signature peptide.  
A ‘fit-for-purpose’ method validation is traditionally used for biomarker assays i.e. the method 
validation should be evaluated based on its intended purpose. (Bower, et al. 2014, Lee 2009, 
Lee, et al. 2006, Stevenson, et al. 2013). Selectivity of the mass spectrometry based biomarker 
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assay is ensured by choosing a unique signature peptide and appropriate mass transitions. 
Additionally, selectivity can be incorporated in the method through selective isolations such as 
protein and peptide immunocapture. Accuracy and precision of the method within an analytical 
batch and between batches is evaluated during validation. As biomarkers are endogenous 
molecules, calibration curve standards and quality control samples are prepared by spiking 
protein reference standards into pooled matrix samples which have low endogenous levels of the 
biomarker (Lee, et al. 2009). Alternatively, a surrogate matrix such as analyte stripped matrix or 
buffer matrix can be used. A parallelism experiment in which comparison of the sensitivity in the 
sample matrix and the surrogate matrix can be used to demonstrate that there are no matrix 
differences between the sample matrix and surrogate matrix (Lee, et al. 2009). In addition, 
storage stability, in-process stability and post preparative stability is also established during 
validation. Method validation ensures that the developed biomarker assay is selective, accurate, 
precise and reproducible. This builds greater confidence in the biomarker based decisions in 
clinical settings.  
In chapter 3, a LC-MS/MS method was developed and validated for measurement of the activity 
of the biomarker protein thymidine kinase 1 (TK1) in serum. TK1 is an enzyme involved in 
DNA synthesis whose activity in serum is indicative of tumor proliferation and the severity of 
blood malignancies (Topolcan, et al. 2008). TK1 activity was measured by monitoring the 
conversion of 3’-deoxy-3’-fluorothymidine (FLT), a specific exogenous substrate for TK1, to 3’-
deoxy-3’-fluorothymidine monophosphate (FLT-MP) (Faria, et al. 2012). Protein precipitation 
and on-line SPE was used for analyte isolation prior to LC-MS/MS analysis. The amount of 
FLT-MP generated was quantified using LC-MS/MS. The method was linear over the range of 
0.5-500 ng/mL for FLT and 2.5-2000 ng/mL for FLT-MP with a mean correlation coefficient of 
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0.9964 and 0.9935 for FLT and FLT-MP, respectively. The lower limit of quantification was 0.5 
ng/mL for FLT and 2.5 ng/ml for FLT-MP. Intra-assay accuracy and inter-assay accuracy was 
within ±12 % for both FLT and FLT-MP. Intra-assay precision was 2.8% to 7.7% for FLT and 
3.3% to 5.8% for FLT-MP. Inter-assay precision was 4.6% to 14.9% for FLT and 4.9% to 14.6% 
for FLT-MP. Typically, an activity assay is more sensitive to formation of product in comparison 
the consumption of the substrate; hence serum TK1 activity was assessed by the formation of 
FLT-MP. Serum TK1 activity was measured in serum from hepatocellular carcinoma (HCC) 
patients and age-matched controls under standardized conditions. A sub-population of the HCC 
patient samples showed an almost 20-fold enhanced TK1 activity compared to the controls. This 
method provided a robust alternative to radiometric and immunochemical assays for rapid and 
selective determination of serum TK1 activity during oncological screening and monitoring. 
In chapter 4, a microflow LC-MS/MS method was developed and validated for measurement of 
the biomarker protein human osteopontin from plasma using a biologically relevant signature 
peptide. Human osteopontin (hOPN) is a secreted cell signaling protein which is implicated in 
the pathogenesis of a variety of disease states, including cardiovascular disorders, cancer, and 
several chronic inflammatory diseases (Lund, et al. 2009, Rodrigues, et al. 2007, Waller, et al. 
2010). The primary integrin binding site on hOPN is 
159
RGDSVVYGLR. This region is also a 
site known to undergo proteolytic cleavage and is devoid of any post-translational 
phosphorylation.  The signature peptide’ (GDSVVYGLR) was chosen from this biologically 
active region of hOPN. The use of a biologically relevant signature peptide ensures that the 
captured hOPN is biologically active.  Immunocapture, using hOPN specific antibodies, was 
used to isolate hOPN from the plasma matrix prior to tryptic digestion. Online sample 
enrichment was performed using column trapping prior to chromatographic separation. Initial 
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method development was carried out using a conventional flow liquid chromatographic (LC) 
system coupled to an AB Sciex API 4000 Qtrap. The method was transferred to a capillary 
microflow Waters ionkey/MS system in order to achieve the detection limits needed for normal 
endogenous concentrations of osteopontin. Immunocapture buffer was used as a surrogate matrix 
for validation studies. Samples were diluted prior to analysis to eliminate matrix effects. The 
method was validated over a range of 25-600 ng/mL. The performance of the method was found 
to be compliant with the USFDA validation guidance (Center for Drug Evaluation and Research 
(U.S.), et al. 2001). 
During method development, the signature peptide was observed to undergo an unexpected 
chymotryptic-like cleavage leading to its degradation. An important objective of this chapter was 
to evaluate the ability of the stable isotope labeled (SIL) peptide GDSVVYGLR* and an 
extended SIL peptide TYDGRGDSVV*YGLRSKSKKF’ as internal standards (IS) to account 
for variability and instability of the signature peptide during digestion. Inherent digestion 
variability was not significantly different with either peptide IS. However, when the trypsin 
activity was varied, the extended SIL peptide was found to be better internal standard to account 
for digestion variability. In the digestion variability studies, the use of extended SIL peptide as 
internal standard limited the total variability within ±30%. Alternatively, when SIL peptide was 
used as internal standard the variability ranged from -67.4% to 50.6 %. 
The applicability of the method for measuring plasma OPN levels was demonstrated by analysis 
of samples obtained from breast cancer patients and healthy individuals.  The method range 
covered both healthy and diseased population plasma OPN concentrations. The plasma OPN 
concentrations in healthy individuals ranged from 38-85 ng/mL with a mean concentration of 
55.4±15.3 ng/mL.  A 1.5-12 fold increase in OPN concentrations, ranging from 85-637 ng/mL, 
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was seen in breast cancer patient samples. Human osteopontin undergoes post-translational 
proteolytic cleavage which can interfere in its quantification in ligand binding assays. The use of 
a biologically relevant signature peptide ensures that the captured hOPN is biologically active. 
Thus, this method is proposed as an alternative to ELISA and for measuring plasma OPN 
concentrations for biomarker applications.  
In chapter 5, prelimary studies were conducted to develop a cell based system to evaluate 
tobacco products for cardiovascular risk based on the LC-MS/MS measurement of secreted 
osteopontin and MMP-3 cleaved osteopontin fragments.  Our first objective was to develop a 
LC-MS/MS to quantify full hOPN and the MMP-3 cleaved hOPN fragments from cell media.  
From our in-silico studies, we predicted that tryptic digestion of hOPN and its MMP-3 cleaved 
N-terminal hOPN fragment would yield two different signature peptides i.e. ‘GDSVVYGLR’ 
and ‘GDSVVYG’, respectively. However, in our preliminary LC-MS/MS evaluation of full 
hOPN tryptic digests, we saw that tryptic digestion resulted in the production of only a small 
amounts of the ‘GDSVVYG’ peptide, thus negating our ability to quantify the MMP-3 N-
terminal hOPN cleaved fragments using LC-MS/MS.  Our second objective was to develop an in 
vitro method for evaluating the cardiovascular risk potential of tobacco products by measuring 
secreted hOPN levels from tobacco extract exposed endothelial cells. EA.hy926 vascular 
endothelial cells were exposed to cigarette smoke extract and its supernatant was evaluated for 
secreted osteopontin levels along with nicotine and solvent controls, using a modified LC-
MS/MS method developed in chapter 4. However, it was observed that the secreted osteopontin 
concentrations in the supernatant of cell culture studies were below detection limits. Since the 
preliminary results did not indicate that this research objective could be addressed with the 
proposed system, this study was terminated. 
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In chapter 6, in a proof-of-concept study, we evaluated the ability of an SIL-peptide IS peptide to 
compensate for immunocapture variability during quantification of human osteopontin (hOPN) 
by immunoaffinity coupled LC-MS/MS. For this study, we modified the LC-MS/MS method to 
quantify hOPN with a hOPN specific antibody that had an epitope present on the SIL-IS peptide. 
Immunocapture variability was induced by varying the antibody amount per well from 150-4500 
ng and analysis was carried out with internal standards added before and after the 
immunocapture step. The immunocapture variability ranged from -80.9 % to 77.0 % when the IS 
was added after immunocapture and from -37.5% to 20.3% when the IS was added before 
immunocapture. The lower variability demonstrates the ability of the SIL-IS peptide to 
compensate for variation during immunocapture. The immunocapture efficiency was 
significantly lower than that of the original method. The low immunocapture efficiency will limit 
the detectability of the method for its biomarker application. Hence, this method was not 
validated.  
 With increase in the biomarker applications in drug development and clinical settings, there is a 
need for improving analytical technology for biomarker quantification. LC-MS/MS shows great 
promise as an analytical tool for quantification of protein biomarkers (Makawita, et al. 2010, 
Ramanathan, et al. 2011, Rauh 2012). We developed and validated a method to precisely and 
accurately measure the activity of serum thymidine kinase 1 using LC-MS/MS. In addition, we 
developed and validated a method to precisely and accurately measure human osteopontin from 
plasmas using LC-MS/MS. The method focused on using a signature peptide from the bioactive 
region of the human osteopontin, thus, enabling better reliability of this method for biomarker 
applications. In addition, our investigations were focused on internal standard correction for 
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protein quantification by LC-MS/MS, and enhanced our present understanding of internal 
standardization for protein quantification. We were able to demonstrate that extended SIL-IS 
peptides can effectively compensate for immunocapture and digestion variability during human 
osteopontin quantification from plasma by LC-MS/MS.  These methods provide an alternative to 
immunoassay quantification for evaluation of protein biomarkers in clinical settings. In the 
future, technological developments in mass spectrometric instrumentation and sample processing 
to achieve lower detection limits coupled with better workflow to achieve more rugged methods 
will result in greater acceptance of mass spectrometry based quantification methods by 
regulatory authorities and the clinical sciences community.  
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